



PCT / (S) 2003 / 003502 #2
Rec'd PCT/PTO 08 FEB 2005



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road


Newport
South Wales
NP10 8QQ
REC'D 30 SEP 2003
WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *AmBrewer*

Dated 22 August 2003

**CERTIFIED COPY OF
PRIORITY DOCUMENT**

Patents Form 1/77

Patents Act 1977
(Rule 16)



09AUG02 E739707-1/000192
P01/7700-0.00-0218473.7

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

N.86243 JCI

2. Patent application number

(The Patent Office will fill in this part)

0218473.7

08 AUG 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

PHARMA PACIFIC PTY. LTD.
103-105 Pipe Road
Laverton North
Victoria 3026
AUSTRALIA

Patents ADP number (*if you know it*)

If the applicant is a corporate body, give the country/state of its incorporation

AUSTRALIA

7589484003

4. Title of the invention

INTERFERON-ALPHA INDUCED GENE

5. Name of your agent (*if you have one*)

J.A. KEMP & CO.

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

14 South Square
Gray's Inn
London
WC1R 5JJ

Patents ADP number (*if you know it*)

26001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number
(*if you know it*)

Date of filing
(*day / month / year*)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(*day / month / year*)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer 'Yes' if:*

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77


9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 48

Claim(s) 4

Abstract 1

Drawing(s) 

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

J.A. Kemp & Co.

Date 8 August 2000

J.A. KEMP & CO.

12. Name and daytime telephone number of person to contact in the United Kingdom

IRVINE, Jonquil Claire
020 7405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 5005
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

INTERFERON-ALPHA INDUCED GENE

Field of the Invention

The present invention relates to identification of a human gene upregulated by interferon- α (IFN- α) administration, the coding sequence of which is believed to be previously unknown. Detection of expression products of this gene may find use in predicting responsiveness to IFN- α and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the isolated novel protein encoded by the same gene is also envisaged.

Background of the Invention

IFN- α is widely used for the treatment of a number of disorders. Disorders which may be treated using IFN- α include neoplastic diseases such as leukemia, lymphomas, and solid tumours, AIDS-related Kaposi's sarcoma and viral infections such as chronic hepatitis. IFN- α has also been proposed for administration via the oromucosal route for the treatment of autoimmune, mycobacterial, neurodegenerative, parasitic and viral disease. In particular, IFN- α has been proposed, for example, for the treatment of multiple sclerosis, leprosy, tuberculosis, encephalitis, malaria, cervical cancer, genital herpes, hepatitis B and C, HIV, HPV and HSV-1 and 2. It has also been suggested for the treatment of arthritis, lupus and diabetes. Neoplastic diseases such as multiple myeloma, hairy cell leukemia, chronic myelogenous leukemia, low grade lymphoma, cutaneous T-cell lymphoma, carcinoid tumours, cervical cancer, sarcomas including Kaposi's sarcoma, kidney tumours, carcinomas including renal cell carcinoma, hepatic cellular carcinoma, nasopharyngeal carcinoma, haematological malignancies, colorectal cancer, glioblastoma, laryngeal papillomas, lung cancer, colon cancer, malignant melanoma and brain tumours are also suggested as being treatable by administration of IFN- α via the oromucosal route, i.e. the oral route or the nasal route.

IFN- α is a member of the Type 1 interferon family, which exert their characteristic biological activities through interaction with the Type 1 interferon receptor. Other Type 1 interferons include IFN- β , IFN- ω and IFN- τ .

Unfortunately, not all potential patients for treatment with a Type 1 interferon such as interferon- α , particularly, for example, patients suffering from chronic viral

hepatitis, neoplastic disease and relapsing remitting multiple sclerosis, respond favourably to Type 1 interferon therapy and only a fraction of those who do respond exhibit long-term benefit. The inability of the physician to confidently predict the therapeutic outcome of Type 1 interferon treatment raises serious concerns as to the cost-benefit ratio of such treatment, not only in terms of wastage of an expensive biopharmaceutical and lost time in therapy, but also in terms of the serious side effects to which the patient is exposed. Furthermore, abnormal production of IFN- α has been shown to be associated with a number of autoimmune diseases. For these reasons, there is much interest in identifying Type 1 interferon responsive genes since Type 1 interferons exert their therapeutic action by modulating the expression of a number of genes. Indeed, it is the specific pattern of gene expression induced by Type 1 interferon treatment that determines whether a patient will respond favourably or not to the treatment.

Summary of the Invention

A human gene cDNA has now been identified as corresponding to a mouse gene upregulated by administration of IFN- α by an oromucosal route or intravenously and is believed to represent a novel DNA. The corresponding human gene is thus now also designated an IFN- α upregulated gene.

The HuIFRG 217.1 gene encodes a protein of 1,933 amino acids and is referred to below as HuIFRG 217.1 protein. This protein shows homology to a 1298 amino acid protein (KIAA 268), a 419 amino acid protein (AK022542) and a 556 amino acid protein (AK00177C) all of unknown function. The sequences of these proteins are publicly available, for example from the GenBankTM database. The HuIFRG 217.1 protein is also related to an earlier published polypeptide known as HuIFRG 70, the amino acid sequence of which is given in SEQ ID NO: 4. HuIFRG 217.7 and HuIFRG 70 are different transcripts of the same gene. It is believed that the HuIFRG 70 transcript is a shorter variant of the mature HuIFRG 217.1 mature protein. The existence of HuIFRG 217.1 was previously unrecognised. HuIFRG 217.1 protein, and functional variants thereof, are now envisaged as therapeutic agents, in particular for use as an anti-viral, anti-tumour or immunomodulatory agent. For example, they may be used in the treatment of autoimmune, mycobacterial, neurodegenerative, parasitic or viral disease,

arthritis, diabetes, lupus, multiple sclerosis, leprosy, tuberculosis, encephalitis, malaria, cervical cancer, genital herpes, hepatitis B or C, HIV, HPV, HSV-1 or 2, or neoplastic disease such as multiple myeloma, hairy cell leukemia, chronic myelogenous leukemia, low grade lymphoma, cutaneous T-cell lymphoma, carcinoid tumours, cervical cancer, sarcomas including Kaposi's sarcoma, kidney tumours, carcinomas including renal cell carcinoma, hepatic cellular carcinoma, nasopharyngeal carcinoma, haematological malignancies, colorectal cancer, glioblastoma, laryngeal papillomas, lung cancer, colon cancer, malignant melanoma or brain tumours. In other words, such a protein may find use in treating any Type 1 interferon treatable disease.

Determination of the level of HuIFRG 217.1 protein or a naturally-occurring variant thereof, or the corresponding mRNA, in cell samples of Type 1 interferon-treated patients, e.g. patients treated with IFN- α , e.g. such as by the oromucosal route or intravenously, may also be used to predict responsiveness to such treatment. It is believed that alternatively, and more preferably, such responsiveness may be judged, for example, by treating a sample of human peripheral blood mononuclear cells *in vitro* with a Type 1 interferon and looking for upregulation or downregulation of an expression product, preferably mRNA, corresponding to the HuIFRG 217.1 gene.

According to a first aspect of the invention, there is thus provided an isolated polypeptide comprising;

- (i) the amino acid sequence of SEQ ID NO: 2;
- (ii) an allelic or species variant of a sequence of (i);
- (iii) a variant of a sequence of (i) having at least 60% identity over the full length of SEQ ID NO: 2 and having substantially similar function selected from immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity; or
- (iv) a fragment of (i) or (ii) which does not have the amino acid sequence of any of SEQ ID NO: 4, an allelic or species variant of the sequence of SEQ ID NO: 4 or a fragment thereof; and which retains substantially similar function selected from immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity.

The invention also provides such a protein for use in therapeutic treatment of a human or non-human animal, more particularly for use as an anti-viral, anti-tumour or

immunomodulatory agent. As indicated above, such use may extend to any Type 1 interferon treatable disease.

According to another aspect of the invention, there is provided an isolated polynucleotide encoding a polypeptide of the invention as defined above or a complement thereof. Such a polynucleotide will typically include a sequence comprising:

- (a) the nucleic acid of SEQ ID NO: 1 or the coding sequence thereof and/or a sequence complementary thereto;
- (b) a sequence which hybridises, e.g. under stringent conditions, to a sequence complementary to a sequence as defined in (a);
- (c) a sequence which is degenerate as a result of the genetic code to a sequence as defined in (a) or (b);
- (d) a sequence having at least 60% identity to a sequence as defined in (a), (b) or (c).

A polynucleotide of the invention will typically be a polynucleotide as described above but will not encode a polypeptide selected from:

- (i) the amino acid sequence of SEQ ID NO: 4;
- (ii) a variant thereof having substantially similar function selected from immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity; or
- (iii) a fragment of (i) or (ii) which retains substantially similar function selected from immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity.

A polynucleotide of the invention will typically not consist of:

- (a) the nucleic acid sequence of SEQ ID NO: 3 or the coding sequence thereof and/or a sequence complementary thereto;
- (b) a sequence which hybridises to a sequence as defined in (a);
- (c) a sequence that is degenerate as a result of the genetic code to a sequence as defined in (a) or (b); or
- (d) a sequence having at least 60% identity to a sequence as defined in (a), (b) or (c).

The invention also provides;

- an expression vector which comprises a polynucleotide of the invention and which is capable of expressing a polypeptide of the invention;
- a host cell containing an expression vector of the invention;
- an antibody specific for a polypeptide of the invention;
- 5 - a method of treating a subject having a Type 1 interferon treatable disease, which method comprises administering to the said patient an effective amount of HuIFRG 217.1 protein or a functional variant thereof,
- use of such a polypeptide in the manufacture of a medicament for use in therapy as an anti-viral or anti-tumour or immunomodulatory agent, more particularly for
- 10 use in treatment of a Type 1 interferon treatable disease;
- a pharmaceutical composition comprising a polypeptide of the invention and a pharmaceutically acceptable carrier or diluent;
- a method of producing a polypeptide of the invention, which method comprises maintaining host cells of the invention under conditions suitable for obtaining
- 15 expression of the polypeptide and isolating the said polypeptide;
- a polynucleotide of the invention, e.g. in the form of an expression vector, which directs expression *in vivo* of a polypeptide as defined above for use in therapeutic treatment of a human or non-human animal, more particularly for use as an anti-viral, anti-tumour or immunomodulatory agent;
- 20 - a pharmaceutical composition comprising such a polynucleotide and a pharmaceutically acceptable carrier or diluent;
- a method of treating a subject having a Type 1 interferon treatable disease, which method comprises administering to said patient an effective amount of such a polynucleotide;
- 25 - use of such a polynucleotide in the manufacture of a medicament, e.g. a vector preparation, for use in therapy as an anti-viral, anti-tumour or immunomodulatory agent, more particularly for use in treating a Type 1 interferon treatable disease; and
- a method of identifying a compound having immunomodulatory activity and/or
- 30 anti-viral activity and/or anti-tumour activity comprising providing a cell capable of expressing HuIFRG 217.1 protein or a naturally occurring variant thereof,

incubating said cell with a compound under test and monitoring for upregulation of HuIFRG 217.1 gene expression.

In a still further aspect, the invention provides a method of predicting responsiveness of a patient to treatment with a Type 1 interferon, e.g. IFN- α treatment (such as IFN- α treatment by the oromucosal route or a parenteral route, for example, intravenously, subcutaneously, or intramuscularly), which comprises determining the level of HuIFRG 217.1 protein or a naturally-occurring variant thereof, e.g. an allelic variant, or the corresponding mRNA, in a cell sample from said patient, e.g. a blood sample, wherein said sample is obtained from said patient following administration of a Type 1 interferon, e.g. IFN- α by an oromucosal route or intravenously, or is treated prior to said determining with a Type 1 interferon such as IFN- α *in vitro*. The invention also extends to kits for carrying out such testing.

Brief description of the Sequences

SEQ. ID. No.1 is the amino acid sequence of human protein HuIFRG 217.1 and its encoding cDNA.

SEQ. ID. No.2 is the amino acid sequence alone of HuIFRG 217.1 protein.

SEQ. ID. No. 3 is the amino acid sequence of human protein HuIFRG 70 and its encoding cDNA.

SEQ. ID. No. 4 is the amino acid sequence alone of HuIFRG 70 protein.

Detailed Description of the Invention

As indicated above, human protein HuIFRG 217.1 and functional variants thereof are now envisaged as therapeutically useful agents, more particularly for use as an anti-viral, anti-tumour or immunomodulatory agent.

A variant of HuIFRG 217.1 protein for this purpose may be a naturally occurring variant, either an allelic variant or species variant, which has substantially the same functional activity as HuIFRG 217.1 protein and is also upregulated in response to administration of IFN- α . Alternatively, a variant of HuIFRG 217.1 protein for therapeutic use may comprise a sequence which varies from SEQ. ID. No. 2 but which is a non-natural mutant.

The term "functional variant" refers to a polypeptide which has the same essential character or basic function of HuIFRG 217.1 protein. The essential character of HuIFRG 217.1 protein may be deemed to be as an immunomodulatory peptide. A functional variant polypeptide may show additionally or alternatively anti-viral activity and/or anti-tumour activity.

Desired anti-viral activity may, for example, be tested as follows. A sequence encoding a variant to be tested is cloned into a retroviral vector such as a retroviral vector derived from the Moloney murine leukemia virus (MoMuLV) containing the viral packaging signal ψ , and a drug-resistance marker. A pantropic packaging cell line containing the viral *gag*, and *pol*, genes is then co-transfected with the recombinant retroviral vector and a plasmid, pVSV-G, containing the vesicular stomatitis virus envelope glycoprotein in order to produce high-titre infectious replication incompetent virus (Burns *et al.*, Proc. Natl. Acad. Sci. USA **84**, 5232-5236). The infectious recombinant virus is then used to transfect interferon sensitive fibroblasts or lymphoblastoid cells and cell lines that stably express the variant protein are then selected and tested for resistance to virus infection in a standard interferon bio-assay (Tovey *et al.*, Nature, **271**, 622-625, 1978). Growth inhibition using a standard proliferation assay (Mosmann, T., J. Immunol. Methods, **65**, 55-63, 1983) and expression of MHC class I and class II antigens using standard techniques may also be determined.

A desired functional variant of HuIFRG 217.1 may consist essentially of the sequence of SEQ. ID. No. 2. A functional variant of SEQ. ID. No.2 may be a polypeptide which has a least 60% to 70% identity, preferably at least 80% or at least 90% and particularly preferably at least 95%, at least 97% or at least 99% identity with the amino acid sequence of SEQ. ID. No. 2 over a region of at least 20, preferably at least 30, for instance at least 100 contiguous amino acids or over the full length of SEQ. ID. No. 2. In one aspect a desired functional variant shows such a degree of homology over a region of at least 20, preferably at least 30, for instance at least 100 contiguous amino acids of SEQ ID NO. 2, but does not show such homology to the amino acid sequence of SEQ ID No. 4. Preferably a desired functional variant shows such a degree of homology over the entire length of SEQ ID NO. 2. For example, a variant may show at least 60%, at least 70%, at least 80% or at least 90% and preferably at least 95%, at

least 97% or at least 99% identity over the full length of the amino acid sequence of SEQ. ID. No. 2. Methods of measuring protein identity are well known in the art.

Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions. Conservative substitutions may be made, for example according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other.

ALIPHATIC	Non-polar	G A P
		I L V
	Polar-uncharged	C S T M
		N Q
	Polar-charged	D E
		K R
AROMATIC		H F W Y

Variant polypeptide sequences for therapeutic use in accordance with the invention may be shorter polypeptide sequences, for example, a peptide of at least 20 amino acids or up to 50, 60, 70, 80, 100, 150 or 200 amino acids in length is considered to fall within the scope of the invention provided it retains appropriate biological activity of HuIFRG 217.1 protein. In particular, but not exclusively, this aspect of the invention encompasses the situation when the variant is a fragment of a complete naturally-occurring protein sequence. A preferred fragment of HuIFRG 217.1 protein is derived from a region of the HuIFRG 217.1 amino acid sequence which is not also found in the HuIFRG 70 amino acid sequence given in SEQ ID No. 4. Such a fragment may consist entirely of an amino acid sequence which is not present in SEQ ID No. 4. That is, such a fragment may not comprise the amino acid sequence of SEQ ID NO. 4 or a fragment thereof. Such a fragment of the invention may be a fragment of the amino acid sequence of SEQ ID NO. 2 that includes part of the sequence of SEQ ID NO. 4 and additionally extends beyond the ends of that polypeptide to include further amino acids which are present in SEQ ID NO. 2 but not SEQ ID NO. 4.

Also encompassed by the invention are modified forms of HuIFRG 217.1 protein and fragments thereof which can be used to raise anti-HuIFRG 217.1 protein antibodies. Such variants will comprise an epitope of the HuIFRG 217.1 protein. Preferably, such variants will comprise an epitope of the HuIFRG 217.1 protein which is not present in the HuIFRG 70 protein.

Polypeptides of the invention may be chemically modified, e.g. post-translationally modified. For example, they may be glycosylated and/or comprise modified amino acid residues. They may also be modified by the addition of a sequence at the N-terminus and/or C-terminus, for example by provision of histidine residues or a T7 tag to assist their purification or by the addition of a signal sequence to promote insertion into the cell membrane. Such modified polypeptides fall within the scope of the term "polypeptide" of the invention.

A polypeptide of the invention may be labelled with a revealing label. The revealing label may be any suitable label which allows the polypeptide to be detected. Suitable labels include radioisotopes such as ^{125}I , ^{35}S or enzymes, antibodies, polynucleotides and linkers such as biotin. Labelled polypeptides of the invention may be used in assays. In such assays it may be preferred to provide the polypeptide attached to a solid support. The present invention also relates to such labelled and/or immobilised polypeptides packaged in the form of a kit in a container. The kit may optionally contain other suitable reagent(s), control(s) or instructions and the like.

The polypeptides of the invention may be made synthetically or by recombinant means. Such polypeptides of the invention may be modified to include non-naturally occurring amino acids, e.g. D amino acids. Variant polypeptides of the invention may have modifications to increase stability *in vitro* and/or *in vivo*. When the polypeptides are produced by synthetic means, such modifications may be introduced during production. The polypeptides may also be modified following either synthetic or recombinant production.

A number of side chain modifications are known in the protein modification art and may be present in polypeptides of the invention. Such modifications include, for example, modifications of amino acids by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 , amidination with methylacetimidate or acylation with acetic anhydride.

Polypeptides of the invention will be in substantially isolated form. It will be understood that the polypeptides may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated. A polypeptide of the invention may also be in substantially purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 90%, for example more than 95%, 98% or 99%, by weight of polypeptide in the preparation is a polypeptide of the invention.

Polynucleotides

The invention also includes isolated nucleotide sequences that encode HuIFRG 217.1 protein or a variant thereof as well as isolated nucleotide sequences which are complementary thereto. The nucleotide sequence may be DNA or RNA, single or double stranded, including genomic DNA, synthetic DNA or cDNA. Preferably the nucleotide sequence is a DNA sequence and most preferably, a cDNA sequence.

As indicated above, such a polynucleotide will typically include a sequence comprising:

- (a) the nucleic acid of SEQ. ID. No. 1 or the coding sequence thereof and/or a sequence complementary thereto;
- (b) a sequence which hybridises, e.g. under stringent conditions, to a sequence complementary to a sequence as defined in (a);
- (c) a sequence which is degenerate as a result of the genetic code to a sequence as defined in (a) or (b);
- (d) a sequence having at least 60% identity to a sequence as defined in (a), (b) or (c).

Polynucleotides comprising an appropriate coding sequence can be isolated from human cells or synthesised according to methods well known in the art, as described by way of example in Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual*, 2nd edition, Cold Spring Harbor Laboratory Press.

Polynucleotides of the invention may include within them synthetic or modified nucleotides. A number of different types of modification to polynucleotides are known in the art. These include methylphosphonate and phosphothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. Such modifications

may be carried out in order to enhance the *in vivo* activity or lifespan of polynucleotides of the invention.

Typically a polynucleotide of the invention will include a sequence of nucleotides, which may preferably be a contiguous sequence of nucleotides, which is capable of hybridising under selective conditions to the coding sequence or the complement of the coding sequence of SEQ. ID. No. 1. A polynucleotide of the invention may be a species or allelic variant of the polynucleotide sequence of coding sequence of SEQ ID NO: 1. Such hybridisation will occur at a level significantly above background. Background hybridisation may occur, for example, because of other cDNAs present in a cDNA library. The signal level generated by the interaction between a polynucleotide of the invention and the coding sequence or complement of the coding sequence of SEQ. ID. No. 1 will typically be at least 10 fold, preferably at least 100 fold, as intense as interactions between other polynucleotides and the coding sequence of SEQ. ID. No. 1. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with ^{32}P . Selective hybridisation may typically be achieved using conditions of low stringency (0.3M sodium chloride and 0.03M sodium citrate at about 40°C), medium stringency (for example, 0.3M sodium chloride and 0.03M sodium citrate at about 50°C) or high stringency (for example, 0.03M sodium chloride and 0.03M sodium citrate at about 60°C).

Preferably the polynucleotide of the invention is not the polynucleotide shown in SEQ ID NO. 3, the coding sequence thereof, the complement thereof or a fragment thereof. Preferably, the polynucleotide is capable of hybridising under such selective conditions to the coding sequence or the complement thereof of SEQ ID No.1, but is not capable of hybridising under such conditions to the coding sequence or the complement of the coding sequence of SEQ ID No. 3.

The coding sequence of SEQ ID No: 1 may be modified by nucleotide substitutions, for example from 1, 2 or 3 to 10, 25, 50 or 100 substitutions. Degenerate substitutions may be made and/or substitutions may be made which would result in a conservative amino acid substitution when the modified sequence is translated, for example as shown in the table above. The coding sequence of SEQ. ID. NO: 1 may alternatively or additionally be modified by one or more insertions and/or deletions and/or by an extension at either or both ends.

A polynucleotide of the invention capable of selectively hybridising to a DNA sequence selected from SEQ. ID No.1, the coding sequence thereof and DNA sequences complementary thereto will be generally at least 60%, preferably at least 70, 80 or 90% and more preferably at least 95% or 97%, homologous to the target sequence. This
5 homology may typically be over a region of at least 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous nucleotides. This homology may be over the entire length of the target sequence. Preferably a polynucleotide of the invention shows such homology to the sequence of SEQ ID NO. 1 or a region thereof but does not show such homology to the sequence of SEQ ID No.3.

10 Any combination of the above mentioned degrees of homology and minimum sized may be used to define polynucleotides of the invention, with the more stringent combinations (i.e. higher homology over longer lengths) being preferred. Thus for example a polynucleotide which is at least 80% homologous over 25, preferably over 30 nucleotides forms may be found suitable, as may be a polynucleotide which is at least
15 90% homologous over 40 nucleotides.

Homologues of polynucleotide or protein sequences as referred to herein may be determined in accordance with well-known means of homology calculation, e.g. protein homology may be calculated on the basis of amino acid identity (sometimes referred to as "hard homology"). For example the UWGCG Package provides the BESTFIT
20 program which can be used to calculate homology, for example used on its default settings, (Devereux *et al.* (1984) *Nucleic Acids Research* **12**, 387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences or to identify equivalent or corresponding sequences, typically used on their default settings, for example as described in Altschul S. F. (1993) *J. Mol. Evol.* **36**,290-300; Altschul, S.
25 F. *et al.* (1990) *J. Mol. Biol.* **215**,403-10.

Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying
30 short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul *et al.*, *supra*). These initial neighbourhood word hits act as seeds for initiating searches to find

HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; 5 or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89,10915-10919) alignments (B) of 50, 10 expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match 15 between two nucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001:

20 Polynucleotides according to the invention have utility in production of the proteins according to the invention, which may take place *in vitro*, *in vivo* or *ex vivo*. In such a polynucleotide, the coding sequence for the desired protein of the invention will be operably-linked to a promoter sequence which is capable of directing expression of the desired protein in the chosen host cell. Such a polynucleotide will generally be in the 25 form of an expression vector. Polynucleotides of the invention, e.g. in the form of an expression vector, which direct expression *in vivo* of a polypeptide of the invention having immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity may also be used as a therapeutic agent.

Expression vectors for such purposes may be constructed in accordance with 30 conventional practices in the art of recombinant DNA technology. They may, for example, involve the use of plasmid DNA. They may be provided with an origin of replication. Such a vector may contain one or more selectable markers genes, for

example an ampicillin resistance gene in the case of a bacterial plasmid. Other features of vectors of the invention may include appropriate initiators, enhancers and other elements, such as for example polyadenylation signals which may be desirable, and which are positioned in the correct orientation, in order to allow for protein expression.

5 Other suitable non-plasmid vectors would be apparent to persons skilled in the art. By way of further example in this regard reference is made again to Sambrook *et al.*, 1989 (supra). Such vectors additionally include, for example, viral vectors. Examples of suitable viral vectors include herpes simplex viral vectors, replication-defective retroviruses, including lentiviruses, adenoviruses, adeno-associated virus, HPV viruses
10 (such as HPV-16 and HPV-18) and attenuated influenza virus vectors.

Promoters and other expression regulation signals may be selected to be compatible with the host cell for which expression is designed. For example, yeast promoters include *S. cerevisiae* GAL4 and ADH promoters, *S. pombe* *nmt1* and *adh* promoter. Mammalian promoters include the metallothionein promoter which can be
15 induced in response to heavy metals such as cadmium and β -actin promoters. Viral promoters such as the SV40 large T antigen promoter or adenovirus promoters may also be used. Other examples of viral promoters which may be employed include the Moloney murine leukemia virus long terminal repeat (MMLV LTR), the rous sarcoma virus (RSV) LTR promoter, the human cytomegalovirus (CMV) IE promoter, and HPV
20 promoters, particularly the HPV upstream regulatory region (URR). Other suitable promoters will be well-known to those skilled in the recombinant DNA art.

An expression vector of the invention may further include sequences flanking the coding sequence for the desired polypeptide of the invention providing sequences homologous to eukaryotic genomic sequences, preferably mammalian genomic
25 sequences, or viral genomic sequences. This will allow the introduction of such polynucleotides of the invention into the genome of eukaryotic cells or viruses by homologous recombination. In particular, a plasmid vector comprising the expression cassette flanked by viral sequences can be used to prepare a viral vector suitable for delivering the polynucleotides of the invention to a mammalian cell.

30 The invention also includes cells *in vitro*, for example prokaryotic or eukaryotic cells, which have been modified to express the HuIFRG 217.1 protein or a variant thereof. Such cells include stable, e.g. eukaryotic, cell lines wherein a polynucleotide

encoding HuIFRG 217.1 protein or a variant thereof is incorporated into the host genome. Host cells of the invention may be mammalian cells or insect cells, lower eukaryotic cells, such as yeast or prokaryotic cells such as bacterial cells. Particular examples of cells which may be modified by insertion of vectors encoding for a polypeptide according to the invention include mammalian HEK293T, CHO, HeLa and COS cells. Preferably a cell line may be chosen which is not only stable, but also allows for mature glycosylation of a polypeptide. Expression may, for example, be achieved in transformed oocytes.

A polypeptide of the invention may be expressed in cells of a transgenic non-human animal, preferably a mouse. A transgenic non-human animal capable of expressing a polypeptide of the invention is included within the scope of the invention.

Polynucleotides according to the invention may also be inserted into vectors as described above in an antisense orientation in order to provide for the production of antisense sequences. Antisense RNA or other antisense polynucleotides may also be produced by synthetic means.

A polynucleotide, e.g. in the form of an expression vector, capable of expressing *in vivo* an antisense sequence to a coding sequence for the amino acid sequence defined by SEQ. ID. No. 2, or a naturally-occurring variant thereof, for use in therapeutic treatment of a human or non-human animal is also envisaged as constituting an additional aspect of the invention. Such a polynucleotide will find use in treatment of diseases associated with upregulation of HuIFRG 217.1 protein.

Polynucleotides of the invention extend to sets of primers for nucleic acid amplification which target sequences within the cDNA for a polypeptide of the invention, e.g. pairs of primers for PCR amplification. The invention also provides probes suitable for targeting a sequence within a cDNA or RNA for a polypeptide of the invention which may be labelled with a revealing label, e.g. a radioactive label or a non-radioactive label such as an enzyme or biotin. Such probes may be attached to a solid support. Such a solid support may be a micro-array (also commonly referred to as nucleic acid, probe or DNA chip) carrying probes for further nucleic acids, e.g. mRNAs or amplification products thereof corresponding to other Type 1 interferon upregulated genes, e.g. such genes identified as upregulated in response to oromucosal or intravenous administration of IFN- α . Methods for constructing such micro-arrays are well-known

(see, for example, EP-B 0476014 and 0619321 of Affymax Technologies N.V. and Nature Genetics Supplement January 1999 entitled "The Chipping Forecast").

5 The nucleic acid sequence of such a primer or probe will preferably be at least 10, preferably at least 15 or at least 20, for example at least 25, at least 30 or at least 40 nucleotides in length. It may, however, be up to 40, 50, 60, 70, 100 or 150 nucleotides in length or even longer. Preferably the primer or probe is chosen to target sequences within the cDNA for the HuIFRG 217.1 protein which are not present in the cDNA for the HuIFRG 70 protein.

10 Another aspect of the invention is the use of probes or primers of the invention to identify mutations in HuIFRG 217.1 genes, for example single nucleotide polymorphisms (SNPs).

As indicated above, in a still further aspect the present invention provides a method of identifying a compound having immunomodulatory activity and/or antiviral activity and/or anti-tumour activity comprising providing a cell capable of expressing HuIFRG 217.1 protein or a naturally-occurring variant thereof, incubating said cell with a compound under test and monitoring for upregulation of HuIFRG 217.1 gene expression. Such monitoring may be by probing for mRNA encoding HuIFRG 217.1 protein or a naturally-occurring variant thereof. Alternatively antibodies or antibody fragments capable of specifically binding one or more of HuIFRG 217.1 and naturally-occurring variants thereof may be employed.

Antibodies

According to another aspect, the present invention also relates to antibodies (for example polyclonal or preferably monoclonal antibodies, chimeric antibodies, humanised antibodies and fragments thereof which retain antigen-binding capability) which have been obtained by conventional techniques and are specific for a polypeptide of the invention. Such antibodies could, for example, be useful in purification, isolation or screening methods involving immunoprecipitation and may be used as tools to further elucidate the function of HuIFRG 217.1 protein or a variant thereof. They may be therapeutic agents in their own right. Such antibodies may be raised against specific epitopes of proteins according to the invention. Antibodies of the invention are antibodies which bind specifically to the HuIFRG 217.1 protein. In one embodiment,

such an antibody specifically binds an epitope within the HuIFRG217.1 protein, but does not specifically bind the HuIFRG 70 protein. An antibody specifically binds to a protein when it binds with high affinity to the protein for which it is specific but does not bind or binds with only low affinity to other proteins. A variety of protocols for competitive binding or immunoradiometric assays to determine the specific binding capability of an antibody are well-known.

Pharmaceutical compositions

A polypeptide of the invention is typically formulated for administration with a pharmaceutically acceptable carrier or diluent. The pharmaceutical carrier or diluent may be, for example, an isotonic solution. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methyl cellulose, carboxymethylcellulose or polyvinyl pyrrolidone; desegregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film coating processes.

Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methyl cellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

Solutions for intravenous administration or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

A suitable dose of HuIFRG 217.1 protein or a functional analogue thereof for use
5 in accordance with the invention may be determined according to various parameters,
especially according to the substance used; the age, weight and condition of the patient to
be treated; the route of administration; and the required regimen. Again, a physician will
be able to determine the required route of administration and dosage for any particular
patient. A typical daily dose may be from about 0.1 to 50 mg per kg, preferably from
10 about 0.1mg/kg to 10mg/kg of body weight, according to the activity of the specific
inhibitor, the age, weight and condition of the subject to be treated, and the frequency
and route of administration. Preferably, daily dosage levels may be from 5 mg to 2 g.

A polynucleotide of the invention suitable for therapeutic use will also typically
be formulated for administration with a pharmaceutically acceptable carrier or diluent.
15 Such a polynucleotide may be administered by any known technique whereby expression
of the desired polypeptide can be attained *in vivo*. For example, the polynucleotide may
be introduced by injection, preferably intradermally, subcutaneously or intramuscularly.
Alternatively, the nucleic acid may be delivered directly across the skin using a particle-
mediated delivery device. A polynucleotide of the invention suitable for therapeutic
20 nucleic acid may alternatively be administered to the oromucosal surface for example by
intranasal or oral administration.

A non-viral vector of the invention suitable for therapeutic use may, for example,
be packaged into liposomes or into surfactant containing vector delivery particles.
Uptake of nucleic acid constructs of the invention may be enhanced by several known
25 transfection techniques, for example those including the use of transfection agents.
Examples of these agents include cationic agents, for example calcium phosphate and
DEAE dextran and lipofectants, for example lipopfectam and transfectam. The dosage
of the nucleic acid to be administered can be varied. Typically, the nucleic acid will be
administered in the range of from 1pg to 1mg, preferably from 1pg to 10 μ g nucleic acid
30 for particle-mediated gene delivery and from 10 μ g to 1 mg for other routes.

Prediction of Type 1 interferon responsiveness

As also indicated above, in a still further aspect the present invention provides a method of predicting responsiveness of a patient to treatment with a Type 1 interferon, e.g. IFN- α treatment such as IFN- α treatment by an oromucosal route or intravenously, which comprises determining the level of HuIFRG 217.1 protein or a naturally-occurring variant thereof, or the corresponding mRNA, in a cell sample from said patient, wherein said sample is taken from said patient following administration of a Type 1 interferon or is treated prior to said determining with a Type 1 interferon *in vitro*.

Preferably, the Type 1 interferon for testing responsiveness will be the Type 1 interferon selected for treatment. It may be administered by the proposed treatment route and at the proposed treatment dose. Preferably, the subsequent sample analysed may be, for example, a blood sample or a sample of peripheral blood mononuclear cells (PBMCs) isolated from a blood sample.

More conveniently and preferably, a sample obtained from the patient comprising PBMCs isolated from blood may be treated *in vitro* with a Type 1 interferon, e.g. at a dosage range of about 1 to 10,000 IU/ml. Such treatment may be for a period of hours, e.g. about 7 to 8 hours. Preferred treatment conditions for such *in vitro* testing may be determined by testing PBMCs taken from normal donors with the same interferon and looking for upregulation of an appropriate expression product. Again, the Type 1 interferon employed will preferably be the Type 1 interferon proposed for treatment of the patient, e.g. recombinant IFN- α . PBMCs for such testing may be isolated in conventional manner from a blood sample using Ficoll-Hypaque density gradients. An example of a suitable protocol for such *in vitro* testing of Type 1 interferon responsiveness is provided in Example 3 below.

The sample, if appropriate after *in vitro* treatment with a Type 1 interferon, may be analysed for the level of HuIFRG 217.1 protein or a naturally-occurring variant thereof. This may be done using an antibody or antibodies capable of specifically binding one or more of HuIFRG 217.1 protein and naturally-occurring variants thereof, e.g. allelic variants thereof. Preferably, however, the sample will be analysed for mRNA encoding HuIFRG 217.1 protein or a naturally-occurring variant thereof. Such mRNA analysis may employ any of the techniques known for detection of mRNAs, e.g.

Northern blot detection or mRNA differential display. A variety of known nucleic acid amplification protocols may be employed to amplify any mRNA of interest present in the sample, or a portion thereof, prior to detection. The mRNA of interest, or a corresponding amplified nucleic acid, may be probed for using a nucleic acid probe attached to a solid support. Such a solid support may be a micro-array as previously discussed above carrying probes to determine the level of further mRNAs or amplification products thereof corresponding to Type 1 interferon upregulated genes, e.g. such genes identified as upregulated in response to oromucosal or intravenous administration of IFN- α .

The following examples illustrate the invention:

Examples

Example 1

Previous experiments had shown that the application of 5 μ l of crystal violet to each nostril of a normal adult mouse using a P20 Eppendorf micropipette resulted in an almost immediate distribution of the dye over the whole surface of the oropharyngeal cavity. Staining of the oropharyngeal cavity was still apparent some 30 minutes after application of the dye. These results were confirmed by using 125 I-labelled recombinant human IFN- α 1-8 applied in the same manner. The same method of administration was employed to effect oromucosal administration in the studies which are described below.

Six week old, male DBA/2 mice were treated with either 100,000 IU of recombinant murine interferon α (IFN α) purchased from Life Technologies Inc, in phosphate buffered saline (PBS), 10 μ g of recombinant human interleukin 15 (IL-15) purchased from Protein Institute Inc, PBS containing 100 μ g/ml of bovine serum albumin (BSA), or left untreated. Eight hours later, the mice were sacrificed by cervical dislocation and the lymphoid tissue was removed surgically from the oropharyngeal cavity and snap frozen in liquid nitrogen and stored at -80°C. RNA was extracted from the lymphoid tissue by the method of Chomczynski and Sacchi 1987, (Anal. Biochem. 162, 156-159) and subjected to mRNA Differential Display Analysis (Lang, P. and Pardee, A.B., Science, 257, 967-971).

Differential Display Analysis

Differential display analysis was carried out using the "Message Clean" and "RNA image" kits of the GenHunter Corporation essentially as described by the manufacturer. Briefly, RNA was treated with RNase-free DNase, and 1 µg was reverse-transcribed in 100 µl of reaction buffer using either one or the other of the three one-base anchored oligo-(dT) primers A, C, or G. RNA was also reverse-transcribed using one or the other of the 9 two-base anchored oligo-(dT) primers AA, CC, GG, AC, CA, GA, AG, CG, GC. All the samples to be compared were reverse transcribed in the same experiment, separated into aliquots and frozen. The amplification was performed with only 1 µl of the reverse transcription sample in 10 µl of amplification mixture containing *Taq* DNA polymerase and α -³³P dATP (3,000 Ci/mmol). Eighty 5' end (HAP) random sequence primers were used in combination with each of the (HT11) A, C, G, AA, CC, GG, AC, CA, GA, AG, CG or GC primers. Samples were then run on 7% denaturing polyacrylamide gels and exposed to autoradiography. Putative differentially expressed bands were cut out, reamplified according to the instructions of the supplier, and further used as probes to hybridize Northern blots of RNA extracted from the oropharyngeal cavity of IFN treated, IL-15 treated, and excipient treated animals.

Cloning and Sequencing

Re-amplified bands from the differential display screen were cloned in the *Sfr* 1 site of the pPCR-Script SK(+) plasmid (Stratagene) and cDNAs amplified from the rapid amplification of cDNA ends were isolated by TA cloning in the pCR3 plasmid (Invitrogen). DNA was sequenced using an automatic di-deoxy sequencer (Perkin Elmer ABI PRISM 377).

Isolation of Human cDNA

Differentially expressed murine 3' sequences identified from the differential display screen were compared with random human expressed sequence tags (EST) present in the dbEST database of GenBank™ of the United States National Center for Biotechnology Information (NCBI). The sequences potentially related to the murine EST isolated from the differential display screen were combined in a contig and used to

construct a human consensus sequence corresponding to a putative cDNA. One such cDNA was found to be 4,135 nucleotides in length. This corresponded to a mouse gene whose expression was found to be enhanced approximately 5-fold in the lymphoid tissue of the oral cavity of mice following oromucosal administration of recombinant murine IFN- α .

In order to establish that this putative cDNA corresponded to an authentic human gene, primers derived from the 5' and 3' ends of the consensus sequence were used to synthesise cDNA from mRNA extracted from human peripheral blood leukocytes (PBL) by specific reverse transcription and PCR amplification. A unique cDNA fragment of the predicted size was obtained, cloned and sequenced (SEQ. ID. No. 3). This human cDNA contains an open reading frame (ORF) of 1,857 bp in length at positions 36-1892 encoding a protein of 618 amino acids (SEQ. ID. No. 4). This transcript was named as HuIFRG 70.

Using this HuIFRG 70 sequence, a further cDNA named HuIFRG 217.1 was isolated by bioinformatics on the basis of sequence homology. The HuIFRG 70 sequence was compared with random human expressed sequence tags (EST) present in the dbEST database of Genbank of the United States National Center for Biotechnology Information (NCBI). The sequences potentially related to HuIFRG 70 were combined in a contig and used to construct a further human consensus sequence corresponding to a putative cDNA. One such cDNA was found to be 8,157 nucleotides in length.

In order to establish that this putative cDNA corresponded to an authentic human gene, primers derived from the 5' and 3' ends of the consensus sequence were used to synthesize cDNA from mRNA extracted from human peripheral blood leukocytes (PBL) by specific reverse transcription and PCR amplification. A unique cDNA fragment of the predicted size was obtained, cloned and sequenced (SEQ ID No. 1). This human cDNA contains an open reading frame (ORF) of 5,802 bp in length at positions 101 to 5900 encoding a protein of 1,933 amino acids (SEQ ID No. 2). This transcript was named as HuIFRG 217.1.

30 Example 2

Testing Type 1 interferon responsiveness *in vitro*

Human Daudi cells (a well characterized B lymphoblast cell line) were treated *in vitro* with 10,000 IU/ml of recombinant human IFN- α 2 (Intron A from Schering-Plough) in PBS, with 1,000 IU/ml of recombinant IFN- γ or with an equal volume of PBS alone. Eight hours later the cells were centrifuged (800 x g for 10 minutes) and the cell pellet recovered. Total RNA was extracted from the cell pellet by the method of Chomczynski and Sacchi (Anal. Biochem. (1987) 162, 156-159) and 10.0 μ g of total RNA per sample was subjected to Northern blotting in the presence of glyoxal and hybridised with a cDNA probe for HuIFRG 217.1 mRNA as described by Dandoy-Dron et al.(J. Biol. Chem. (1998) 273, 7691-7697). The blots were first exposed to autoradiography and then quantified using a PhosphorImager according to the manufacturer's instructions. Enhanced levels of mRNA for HuIFRG 217.1 protein (approximately 5-fold) were detected in samples of RNA extracted from IFN- α and from IFN- γ treated cells compared to samples treated with PBS alone.

The same procedure may be used to predict Type 1 interferon responsiveness using peripheral blood mononuclear cells (PBMCs) taken from a patient proposed to be treated with a Type 1 interferon.

SEQUENCE LISTING

<110> PHARMA PACIFY PTY LTD

<120> INTERFERON-ALPHA INDUCED GENE

<130> P.86243 JCI

<160> -4-

<170> PatentIn version 3.0

<210> 1

<211> 8157

<212> DNA

<213> HOMO SAPIENS

<220>

<221> CDS

<222> (101)..(5902)

<223>

<400> 1

caaggcctgg gagttttcca ggaaacgaaa gcgaaagagt caaagttagc ggcccggagt 60

tggcgcggcc	cctgcagtc	ggcggagagc	ggagctgagg	atg	gct	gtg	ccc	ggc	115
				Met	Ala	Val	Pro	Gly	
				1				5	

tcc	ttc	ccg	ctg	ctg	gtc	gag	ggc	tcc	tgg	ggc	ccc	gac	ccc	ccg	aag	163
Ser	Phe	Pro	Leu	Leu	Val	Glu	Gly	Ser	Trp	Gly	Pro	Asp	Pro	Pro	Lys	
			10					15						20		

aac	ttg	aac	acc	aag	ttg	cag	atg	tac	ttc	cag	agc	ccg	aag	agg	tcg	211
Asn	Leu	Asn	Thr	Lys	Leu	Gln	Met	Tyr	Phe	Gln	Ser	Pro	Lys	Arg	Ser	
			25					30						35		

gga	ggc	ggc	gag	tgt	gag	gtc	cgc	cag	gat	ccc	agg	agc	cca	tcc	cgc	259
Gly	Gly	Gly	Glu	Cys	Glu	Val	Arg	Gln	Asp	Pro	Arg	Ser	Pro	Ser	Arg	
			40				45							50		

ttc	ctg	gtg	ttc	ttc	tac	ccg	gag	gac	ggg	aaa	tgg	cgg	cag	ggc	acg	307
Phe	Leu	Val	Phe	Phe	Tyr	Pro	Glu	Asp	Gly	Lys	Trp	Arg	Gln	Gly	Thr	
			55				60							65		

cac	ggg	agg	gtg	acc	cgc	ccg	act	tcg	gcg	gct	gct	gta	gcg	gag	gcg	355
His	Gly	Arg	Val	Thr	Arg	Pro	Thr	Ser	Ala	Ala	Ala	Val	Ala	Glu	Ala	
			70				75					80			85	

ctt	aat	ggc	gcg	gcc	ccg	agg	tgg	cgg	cgg	aac	cgc	gca	agt	aac	tct	403
Leu	Asn	Gly	Ala	Ala	Arg	Arg	Trp	Arg	Arg	Asn	Arg	Ala	Ser	Asn	Ser	
			90							95					100	

tta	tcc	ctc	gat	cgt	ttt	ctg	tct	ttc	cct	gtt	gtg	gtg	gtg	tta	ttg	451
Leu	Ser	Leu	Asp	Arg	Phe	Leu	Ser	Phe	Pro	Val	Val	Val	Val	Leu	Leu	
			105							110					115	

ttt gtt gtt gtt gtt gtg gaa gtg agt cta tcc tct tat cat cct ttt Phe Val Val Val Val Val Glu Val Ser Leu Ser Ser Tyr His Pro Phe 120 125 130	499
ctg tct ttt cct gtt gtt att att ctt gtg tgg gga agg aaa ctg att Leu Ser Phe Pro Val Val Ile Ile Leu Val Trp Gly Arg Lys Leu Ile 135 140 145	547
aag aaa cgt ggc aag tca cag aga ttc ctt gtg gtt ctt gga gat tcc Lys Lys Arg Gly Lys Ser Gln Arg Phe Leu Val Val Leu Gly Asp Ser 150 155 160 165	595
cag ggg tcc cgg ggt cac ttg gga gag ggg cag agg cgc tac cta aaa Gln Gly Ser Arg Gly His Leu Gly Glu Gly Gln Arg Arg Tyr Leu Lys 170 175 180	643
tca cac tgc ctg aat gtc aac gta gag ccg tca cag cgg cca cat tgg Ser His Cys Leu Asn Val Asn Val Glu Pro Ser Gln Arg Pro His Trp 185 190 195	691
agg ggc tgt cga tcg acc aca gtt cgg cag aag gtt ctg gag aga aaa Arg Gly Cys Arg Ser Thr Thr Val Arg Gln Lys Val Leu Glu Arg Lys 200 205 210	739
aat cat gag ttg gta tgg caa gga aaa gga aca ttc aag tta act gtc Asn His Glu Leu Val Trp Gln Gly Lys Gly Thr Phe Lys Leu Thr Val 215 220 225	787
cag tta cct gca acc cca gat gaa atc gat cat gtc ttt gaa gag gaa Gln Leu Pro Ala Thr Pro Asp Glu Ile Asp His Val Phe Glu Glu Glu 230 235 240 245	835
ctt cta aca aaa gca aat gtg tca gaa gaa ttg gat aca aaa ctc cct Leu Leu Thr Lys Ala Asn Val Ser Glu Glu Leu Asp Thr Lys Leu Pro 250 255 260	883
ctt gat ggt gga tta gac aaa atg gaa gat atc cca gag gaa tgt gaa Leu Asp Gly Gly Leu Asp Lys Met Glu Asp Ile Pro Glu Glu Cys Glu 265 270 275	931
aat att tcc tct ttg gtg gca ttt gaa aac ctc aag gca aat gtg act Asn Ile Ser Ser Leu Val Ala Phe Glu Asn Leu Lys Ala Asn Val Thr 280 285 290	979
gac ata atg cta atc ttg tta gtg gag aac ata agt ggc ctg tct aat Asp Ile Met Leu Ile Leu Leu Val Glu Asn Ile Ser Gly Leu Ser Asn 295 300 305	1027
gat gac ttt caa gtg gaa ata ata aga gat ttt gat gtt gct gtt gtt Asp Asp Phe Gln Val Glu Ile Ile Arg Asp Phe Asp Val Ala Val Val 310 315 320 325	1075
acc ttt caa aag cac ata gat act ata aga ttt gtt gat gat tgt acc Thr Phe Gln Lys His Ile Asp Thr Ile Arg Phe Val Asp Asp Cys Thr 330 335 340	1123

aag cac cat tca att aaa caa ctt cag ctt tct cca aga ctt ctg gaa Lys His His Ser Ile Lys Gln Leu Gln Leu Ser Pro Arg Leu Leu Glu 345 350 355	1171
gtg aca aac aca atc agg gtt gaa aac ctg cca cct ggt gct gat gac Val Thr Asn Thr Ile Arg Val Glu Asn Leu Pro Pro Gly Ala Asp Asp 360 365 370	1219
tac agt tta aaa ctt ttc ttt gaa aat ccc tat aat gga ggg gga aga Tyr Ser Leu Lys Leu Phe Phe Glu Asn Pro Tyr Asn Gly Gly Gly Arg 375 380 385	1267
gtt gcc aat gtt gaa tat ttt cct gaa gag agt tca gct ctg att gaa Val Ala Asn Val Glu Tyr Phe Pro Glu Glu Ser Ser Ala Leu Ile Glu 390 395 400 405	1315
ttt ttt gac aga aaa gtg tta gac acc atc atg gcc aca aaa ctc gac Phe Phe Asp Arg Lys Val Leu Asp Thr Ile Met Ala Thr Lys Leu Asp 410 415 420	1363
ttc aat aaa atg cca ctt tct gtg ttc cca tac tat gcc tca ttg ggc Phe Asn Lys Met Pro Leu Ser Val Phe Pro Tyr Tyr Ala Ser Leu Gly 425 430 435	1411
aca gcc ttg tat gga aag gag aag cct ctg atc aag ctt cca gca cca Thr Ala Leu Tyr Gly Lys Glu Lys Pro Leu Ile Lys Leu Pro Ala Pro 440 445 450	1459
ttt gaa gag tca cta gat ctt ccc tta tgg aag ttc tta cag aaa aag Phe Glu Glu Ser Leu Asp Leu Pro Leu Trp Lys Phe Leu Gln Lys Lys 455 460 465	1507
aat cac ctc att gag gag ata aac gat gaa atg agg cgt tgt cac tgt Asn His Leu Ile Glu Glu Ile Asn Asp Glu Met Arg Arg Cys His Cys 470 475 480 485	1555
gag ctc acg tgg tcc caa ctc agt ggt aaa gtt acc atc aga cca gca Glu Leu Thr Trp Ser Gln Leu Ser Gly Lys Val Thr Ile Arg Pro Ala 490 495 500	1603
gcc acc tta gtc aat gaa gga aga ccg aga atc aag acc tgg cag gca Ala Thr Leu Val Asn Glu Gly Arg Pro Arg Ile Lys Thr Trp Gln Ala 505 510 515	1651
gat act tcc aca aca ctc tct agc atc agg tct aaa tat aaa gtc aac Asp Thr Ser Thr Thr Leu Ser Ser Ile Arg Ser Lys Tyr Lys Val Asn 520 525 530	1699
cca att aaa gtg gat cca aca atg tgg gac acc ata aaa aat gat gtg Pro Ile Lys Val Asp Pro Thr Met Trp Asp Thr Ile Lys Asn Asp Val 535 540 545	1747
aaa gat gac agg att ttg att gag ttt gat aca ctt aag gag atg gta Lys Asp Asp Arg Ile Leu Ile Glu Phe Asp Thr Leu Lys Glu Met Val 550 555 560 565	1795

atc tta gca ggg aaa tca gag gat gtc caa agc att gag gta caa gtc Ile Leu Ala Gly Lys Ser Glu Asp Val Gln Ser Ile Glu Val Gln Val 570 575 580	1843
agg gag tta ata gaa agc act act caa aaa att aaa agg gaa gag caa Arg Glu Leu Ile Glu Ser Thr Thr Gln Lys Ile Lys Arg Glu Glu Gln 585 590 595	1891
agt ttg aag gaa aaa atg atc att tct cca ggc agg tat ttt ctt ttg Ser Leu Lys Glu Lys Met Ile Ile Ser Pro Gly Arg Tyr Phe Leu Leu 600 605 610	1939
tgt cac agc agt cta ctg gac cat tta ctc acg gag tgc cca gag ata Cys His Ser Ser Leu Leu Asp His Leu Leu Thr Glu Cys Pro Glu Ile 615 620 625	1987
gag att tgt tac gat aga gtc act caa cac ttg tgc ttg aaa gga cct Glu Ile Cys Tyr Asp Arg Val Thr Gln His Leu Cys Leu Lys Gly Pro 630 635 640 645	2035
agt gca gat gtg tat aaa gca aag tgt gaa atc cag gaa aag gtg tac Ser Ala Asp Val Tyr Lys Ala Lys Cys Glu Ile Gln Glu Lys Val Tyr 650 655 660	2083
acc atg gct cag aaa aac att cag gtt tct cct gag att ttt cag ttt Thr Met Ala Gln Lys Asn Ile Gln Val Ser Pro Glu Ile Phe Gln Phe 665 670 675	2131
ttg caa cag gta aac tgg aaa gaa ttc tct aag tgt ctt ttc ata gca Leu Gln Gln Val Asn Trp Lys Glu Phe Ser Lys Cys Leu Phe Ile Ala 680 685 690	2179
cag aag att ctt gca ctt tat gag cta gag ggt aca act gtt ctc tta Gln Lys Ile Leu Ala Leu Tyr Glu Leu Glu Gly Thr Thr Val Leu Leu 695 700 705	2227
acc agc tgt tct tct gaa gcc ctg tta gaa gca gaa aag caa atg ctc Thr Ser Cys Ser Ser Glu Ala Leu Leu Glu Ala Glu Lys Gln Met Leu 710 715 720 725	2275
agt gcc tta aat tat aag cgc att gaa gtt gag aac aaa gaa gtt ctt Ser Ala Leu Asn Tyr Lys Arg Ile Glu Val Glu Asn Lys Glu Val Leu 730 735 740	2323
cat ggc aag aaa tgg aaa ggg ctc act cac aat ttg ctt aag aaa caa His Gly Lys Lys Trp Lys Gly Leu Thr His Asn Leu Leu Lys Lys Gln 745 750 755	2371
aat tcc tcc cca aac act gta atc atc aat gag tta act tca gaa acc Asn Ser Ser Pro Asn Thr Val Ile Ile Asn Glu Leu Thr Ser Glu Thr 760 765 770	2419
aca gct gaa gtc atc att aca ggc tgt gta aaa gaa gta aat gaa acc Thr Ala Glu Val Ile Ile Thr Gly Cys Val Lys Glu Val Asn Glu Thr 775 780 785	2467

tat aaa ttg ctt ttt aac ttc gtt gaa caa aac atg aaa ata gag aga Tyr Lys Leu Leu Phe Asn Phe Val Glu Gln Asn Met Lys Ile Glu Arg 790 795 800 805	2515
ctg gtt gaa gta aag cct tcc tta gtt att gac tat tta aag aca gaa Leu Val Glu Val Lys Pro Ser Leu Val Ile Asp Tyr Leu Lys Thr Glu 810 815 820	2563
aag aag cta ttc tgg cca aag ata aag aag gta aat gtg cag gta agt Lys Lys Leu Phe Trp Pro Lys Ile Lys Lys Val Asn Val Gln Val Ser 825 830 835	2611
ttc aat cct gag aac aaa caa aaa ggc att tta cta act ggc tca aag Phe Asn Pro Glu Asn Lys Gln Lys Gly Ile Leu Leu Thr Gly Ser Lys 840 845 850	2659
acc gaa gta ctg aag gca gtg gac att gtc aag caa gtc tgg gat tca Thr Glu Val Leu Lys Ala Val Asp Ile Val Lys Gln Val Trp Asp Ser 855 860 865	2707
gtc tgt gtt aaa agt gtc cat act gat aag cca gga gcc aag cag ttc Val Cys Val Lys Ser Val His Thr Asp Lys Pro Gly Ala Lys Gln Phe 870 875 880 885	2755
ttc cag gat aaa gca cgg ttt tat caa agt gag atc aaa cgg ttg ttt Phe Gln Asp Lys Ala Arg Phe Tyr Gln Ser Glu Ile Lys Arg Leu Phe 890 895 900	2803
ggt tgt tac att gaa cta cag gag aat gaa gta atg aag gag gga ggc Gly Cys Tyr Ile Glu Leu Gln Glu Asn Glu Val Met Lys Glu Gly Gly 905 910 915	2851
agc ccc gct ggg cag aag tgc ttc tct cgg aca gtc ttg gcc cct ggc Ser Pro Ala Gly Gln Lys Cys Phe Ser Arg Thr Val Leu Ala Pro Gly 920 925 930	2899
gtt gtg ctg att gtg cag cag ggt gac ttg gca cgg ctt cct gtc gat Val Val Leu Ile Val Gln Gln Gly Asp Leu Ala Arg Leu Pro Val Asp 935 940 945	2947
gtg gtg gtg aat gca tct aat gag gac ctt aag cat tat ggt ggc ctg Val Val Val Asn Ala Ser Asn Glu Asp Leu Lys His Tyr Gly Gly Leu 950 955 960 965	2995
gcc gct gcg ctc tca aaa gca gct ggc cct gag ctc cag gcc gac tgt Ala Ala Ala Leu Ser Lys Ala Ala Gly Pro Glu Leu Gln Ala Asp Cys 970 975 980	3043
gac cag ata gtg aag aga gag ggc aga ctc cta ccg ggc aat gcc acc Asp Gln Ile Val Lys Arg Glu Gly Arg Leu Leu Pro Gly Asn Ala Thr 985 990 995	3091
atc tcc aag gca gga aag ctg ccc tac cac cac gtg atc cat gca Ile Ser Lys Ala Gly Lys Leu Pro Tyr His His Val Ile His Ala 1000 1005 1010	3136

gtg ggg ccc Val Gly Pro 1015	cgc tgg agc gga tat Arg Trp Ser Gly Tyr 1020	gag gcc ccg agg tgt Glu Ala Pro Arg Cys 1025	gtg tac Val Tyr	3181
cta tta agg Leu Leu Arg 1030	aga gct gtg caa ctc Arg Ala Val Gln Leu 1035	agt ctc tgt cta gcc Ser Leu Cys Leu Ala 1040	gaa aaa Glu Lys	3226
tac aag tac Tyr Lys Tyr 1045	cga tcc ata gcc atc Arg Ser Ile Ala Ile 1050	cca gct att agt tct Pro Ala Ile Ser Ser 1055	gga gtc Gly Val	3271
ttt ggc ttt Phe Gly Phe 1060	ccc tta ggc cga tgc Pro Leu Gly Arg Cys 1065	gtg gag acc att gtt Val Glu Thr Ile Val 1070	tct gcc Ser Ala	3316
atc aag gaa Ile Lys Glu 1075	aac ttc caa ttc aag Asn Phe Gln Phe Lys 1080	aag gat gga cac tgc Lys Asp Gly His Cys 1085	ttg aaa Leu Lys	3361
gaa atc tac Glu Ile Tyr 1090	ctt gtg gat gta tct Leu Val Asp Val Ser 1095	gag aag act gtt gag Glu Lys Thr Val Glu 1100	gcc ttt Ala Phe	3406
gca gaa gct Ala Glu Ala 1105	gtg aaa act gta ttt Val Lys Thr Val Phe 1110	aaa gcc acc ctg cca Lys Ala Thr Leu Pro 1115	gat aca Asp Thr	3451
gct gcc ccg Ala Ala Pro 1120	cca ggt tta cca cca Pro Gly Leu Pro Pro 1125	gca gca gcg ggg cct Ala Ala Ala Gly Pro 1130	ggg aaa Gly Lys	3496
aca tca tgg Thr Ser Trp 1135	gaa aaa gga agc ctg Glu Lys Gly Ser Leu 1140	gtg tcc ccg gga ggc Val Ser Pro Gly Gly 1145	ctg cag Leu Gln	3541
atg ctg ttg Met Leu Leu 1150	gtg aaa gag ggt gtg Val Lys Glu Gly Val 1155	cag aat gct aag acc Gln Asn Ala Lys Thr 1160	gat gtt Asp Val	3586
gtt gtc aac Val Val Asn 1165	tcc gtt ccc ttg gat Ser Val Pro Leu Asp 1170	ctc gtg ctt agt aga Leu Val Leu Ser Arg 1175	ggg cct Gly Pro	3631
ctt tct aag Leu Ser Lys 1180	tcc ctc ttg gaa aaa Ser Leu Leu Glu Lys 1185	gct gga cca gag ctc Ala Gly Pro Glu Leu 1190	cag gag Gln Glu	3676
gaa ttg gac Glu Leu Asp 1195	aca gtt gga caa ggg Thr Val Gly Gln Gly 1200	gtg gct gtc agc atg Val Ala Val Ser Met 1205	ggc aca Gly Thr	3721
gtg ctc aaa Val Leu Lys 1210	acc agc agc tgg aat Thr Ser Ser Trp Asn 1215	ctg gac tgt cgc tat Leu Asp Cys Arg Tyr 1220	gtg ctt Val Leu	3766

cac gtg gta	gct ccg gag tgg aga	aat ggt agc aca tct	tca ctc	3811
His Val Val	Ala Pro Glu Trp Arg	Asn Gly Ser Thr Ser	Ser Leu	
1225	1230	1235		
aag ata atg	gaa gac ata atc aga	gaa tgt atg gag atc	act gag	3856
Lys Ile Met	Glu Asp Ile Ile Arg	Glu Cys Met Glu Ile	Thr Glu	
1240	1245	1250		
agc ttg tcc	tta aaa tca att gca	ttt cca gca ata gga	aca gga	3901
Ser Leu Ser	Leu Lys Ser Ile Ala	Phe Pro Ala Ile Gly	Thr Gly	
1255	1260	1265		
aac ttg gga	ttt cct aaa aac ata	ttc gct gaa tta atc	att tca	3946
Asn Leu Gly	Phe Pro Lys Asn Ile	Phe Ala Glu Leu Ile	Ile Ser	
1270	1275	1280		
gag gtg ttc	aaa ttt agt agc aag	aat cag ctg aaa act	tta caa	3991
Glu Val Phe	Lys Phe Ser Ser Lys	Asn Gln Leu Lys Thr	Leu Gln	
1285	1290	1295		
gag gtt cac	ttt ctg ctg cac ccg	agt gat cat gaa aat	att cag	4036
Glu Val His	Phe Leu Leu His Pro	Ser Asp His Glu Asn	Ile Gln	
1300	1305	1310		
gca ttt tca	gat gaa ttt gcc aga	agg gct aat gga aat	ctc gtc	4081
Ala Phe Ser	Asp Glu Phe Ala Arg	Arg Ala Asn Gly Asn	Leu Val	
1315	1320	1325		
agt gac aaa	att ccg aag gct aaa	gat aca caa ggt ttt	tat ggg	4126
Ser Asp Lys	Ile Pro Lys Ala Lys	Asp Thr Gln Gly Phe	Tyr Gly	
1330	1335	1340		
act gtt tct	agc cct gat tca ggt	gtg tat gaa atg aag	att ggc	4171
Thr Val Ser	Ser Pro Asp Ser Gly	Val Tyr Glu Met Lys	Ile Gly	
1345	1350	1355		
tcc atc atc	ttc cag gtg gct tct	gga gat atc acg aaa	gaa gag	4216
Ser Ile Ile	Phe Gln Val Ala Ser	Gly Asp Ile Thr Lys	Glu Glu	
1360	1365	1370		
aca gat gtg	att gta aat tca aca	tca aac tca ttc aat	ctc aaa	4261
Thr Asp Val	Ile Val Asn Ser Thr	Ser Asn Ser Phe Asn	Leu Lys	
1375	1380	1385		
gca ggg gtc	tcc aaa gca att tta	gaa tgt gct gga caa	aat gta	4306
Ala Gly Val	Ser Lys Ala Ile Leu	Glu Cys Ala Gly Gln	Asn Val	
1390	1395	1400		
gaa agg gaa	tgt tct cag caa gct	cag cag cgc aaa aat	gat tat	4351
Glu Arg Glu	Cys Ser Gln Gln Ala	Gln Gln Arg Lys Asn	Asp Tyr	
1405	1410	1415		
ata atc acc	gga ggt gga ttt ttg	agg tgc aag aat atc	att cat	4396
Ile Ile Thr	Gly Gly Gly Phe Leu	Arg Cys Lys Asn Ile	Ile His	
1420	1425	1430		

gta att ggt Val Ile Gly 1435	gga aat gat gtc aag Gly Asn Asp Val Lys 1440	agt tca gtt tcc tct Ser Ser Val Ser Ser 1445	gtt ttg Val Leu 1441
cag gag tgt Gln Glu Cys 1450	gaa aaa aaa aat tac Glu Lys Lys Asn Tyr 1455	tca tcc att tgc ctc Ser Ser Ile Cys Leu 1460	cca gcc Pro Ala 1486
att ggg aca Ile Gly Thr 1465	gga aat gcc aaa caa Gly Asn Ala Lys Gln 1470	cac cca gat aag gtt His Pro Asp Lys Val 1475	gct gaa Ala Glu 14531
gcc ata att Ala Ile Ile 1480	gat gcc att gaa gac Asp Ala Ile Glu Asp 1485	ttt gtc cag aaa gga Phe Val Gln Lys Gly 1490	tca gcc Ser Ala 14576
cag tct gtg Gln Ser Val 1495	aaa aaa gtt aaa gtt Lys Lys Val Lys Val 1500	gtt atc ttt ctg cct Val Ile Phe Leu Pro 1505	caa gta Gln Val 14621
ctg gat gtg Leu Asp Val 1510	ttt tat gcc aac atg Phe Tyr Ala Asn Met 1515	aag aaa aga gaa ggg Lys Lys Arg Glu Gly 1520	act cag Thr Gln 14666
ctt tct tcc Leu Ser Ser 1525	caa cag tct gtg atg Gln Gln Ser Val Met 1530	tct aaa ctt gca tca Ser Lys Leu Ala Ser 1535	ttt ttg Phe Leu 14711
ggc ttt tca Gly Phe Ser 1540	aag caa tct ccc caa Lys Gln Ser Pro Gln 1545	aaa aag aat cat ttg Lys Lys Asn His Leu 1550	gtt ttg Val Leu 14756
gaa aag aaa Glu Lys Lys 1555	aca gaa tca gca act Thr Glu Ser Ala Thr 1560	ttt cgg gtg tgt ggt Phe Arg Val Cys Gly 1565	gaa aat Glu Asn 14801
gtc acg tgt Val Thr Cys 1570	gtg gaa tat gct atc Val Glu Tyr Ala Ile 1575	tcc tgg cta caa gac Ser Trp Leu Gln Asp 1580	ctg att Leu Ile 14846
gaa aaa gaa Glu Lys Glu 1585	cag tgt cct tac acc Gln Cys Pro Tyr Thr 1590	agt gaa gat gag tgc Ser Glu Asp Glu Cys 1595	atc aaa Ile Lys 14891
gac ttt gat Asp Phe Asp 1600	gaa aag gag tat cag Glu Lys Glu Tyr Gln 1605	gag ttg aat gag ctg Glu Leu Asn Glu Leu 1610	cag aag Gln Lys 14936
aag tta aat Lys Leu Asn 1615	att aac att tcc ctg Ile Asn Ile Ser Leu 1620	gac cat aag aga cct Asp His Lys Arg Pro 1625	ttg att Leu Ile 14981
aag gtt ttg Lys Val Leu 1630	gga att agc aga gat Gly Ile Ser Arg Asp 1635	gtg atg cag gct aga Val Met Gln Ala Arg 1640	gat gaa Asp Glu 15026

att gag gcg Ile Glu Ala 1645	atg atc aag aga gtt Met Ile Lys Arg Val 1650	cga ttg gcc aaa gaa Arg Leu Ala Lys Glu 1655	cag gaa Gln Glu	5071
tcc cgg gca Ser Arg Ala 1660	gat tgt atc agt gag Asp Cys Ile Ser Glu 1665	ttt ata gaa tgg Phe Ile Glu Trp Gln 1670	tat aat Tyr Asn	5116
gac aat aac Asp Asn Asn 1675	act tct cat tgt ttt Thr Ser His Cys Phe 1680	aac aaa atg acc aat Asn Lys Met Thr Asn 1685	ctg aaa Leu Lys	5161
tta gag gat Leu Glu Asp 1690	gca agg aga gaa aag Ala Arg Arg Glu Lys 1695	aaa aaa aca gtt gat Lys Lys Thr Val Asp 1700	gtc aaa Val Lys	5206
att aat cat Ile Asn His 1705	cgg cac tac aca gtg Arg His Tyr Thr Val 1710	aac ttg aac aca tac Asn Leu Asn Thr Tyr 1715	act gcc Thr Ala	5251
aca gac aca Thr Asp Thr 1720	aag ggc cac agt tta Lys Gly His Ser Leu 1725	tct gtt cag cgc ctc Ser Val Gln Arg Leu 1730	acg aaa Thr Lys	5296
tcc aaa gtt Ser Lys Val 1735	gac atc cct gca cac Asp Ile Pro Ala His 1740	tgg agt gat atg aag Trp Ser Asp Met Lys 1745	cag cag Gln Gln	5341
aat ttc tgt Asn Phe Cys 1750	gtg gtg gag ctg ctg Val Val Glu Leu Leu 1755	cct agt gat cct gag Pro Ser Asp Pro Glu 1760	tac aac Tyr Asn	5386
acg gtg gca Thr Val Ala 1765	agc aag ttt aat cag Ser Lys Phe Asn Gln 1770	acc tgc tca cac ttc Thr Cys Ser His Phe 1775	aga ata Arg Ile	5431
gag aag att Glu Lys Ile 1780	gag agg atc cag aat Glu Arg Ile Gln Asn 1785	cca gat ctc tgg aat Pro Asp Leu Trp Asn 1790	agc tac Ser Tyr	5476
cag gca aag Gln Ala Lys 1795	aaa aaa act atg gat Lys Lys Thr Met Asp 1800	gcc aag aat ggc cag Ala Lys Asn Gly Gln 1805	aca atg Thr Met	5521
aat gag aag Asn Glu Lys 1810	caa ctc ttc cat ggg Gln Leu Phe His Gly 1815	aca gat gcc ggc tcc Thr Asp Ala Gly Ser 1820	gtg cca Val Pro	5566
cac gtc aat His Val Asn 1825	cga aat ggc ttt aac Arg Asn Gly Phe Asn 1830	cgc agc tat gcc gga Arg Ser Tyr Ala Gly 1835	aag aat Lys Asn	5611
gct gtg gca Ala Val Ala 1840	tat gga aag gga acc Tyr Gly Lys Gly Thr 1845	tat ttt gct gtc aat Tyr Phe Ala Val Asn 1850	gcc aat Ala Asn	5656

tat tct gcc aat gat acg tac tcc aga cca gat gca aat ggg aga Tyr Ser Ala Asn Asp Thr Tyr Ser Arg Pro Asp Ala Asn Gly Arg 1855 1860 1865	5701
aag cat gtg tat tat gtg cga gta ctt act gga atc tat aca cat Lys His Val Tyr Tyr Val Arg Val Leu Thr Gly Ile Tyr Thr His 1870 1875 1880	5746
gga aat cat tca tta att gtg cct cct tca aag aac cct caa aat Gly Asn His Ser Leu Ile Val Pro Pro Ser Lys Asn Pro Gln Asn 1885 1890 1895	5791
cct act gac ctg tat gac act gtc aca gat aat gtg cac cat cca Pro Thr Asp Leu Tyr Asp Thr Val Thr Asp Asn Val His His Pro 1900 1905 1910	5836
agt tta ttt gtg gca ttt tat gac tac caa gca tac cca gag tac Ser Leu Phe Val Ala Phe Tyr Asp Tyr Gln Ala Tyr Pro Glu Tyr 1915 1920 1925	5881
ctt att acg ttt aga aaa taa cactttggta tccttccac aaaattattc Leu Ile Thr Phe Arg Lys 1930	5932
tccatttgta catatctagt tgtaaaacaa gttttagctt ttttttttaa ttcctcttaa	5992
cagatttttc taatatccaa ggatcattct ttgtcgtgc agtcagtctt tcttcagctt	6052
ctctttcata atggaaatga acttattatc ttgagagcaa ataacttgga aaatttaaat	6112
gagataatgc agttgcaact gtgtgtccac aagtatggac atcaaatctg tgggaaaaga	6172
acaggtttgt attttcagga aggagagaat aacagtctta tagacagagg gcacagctaa	6232
gcacagcagc cactgcagga gacaggcccc atgtcaggat gccatagtgc tgtggggagc	6292
acagtattac ccagtgggta gggcttctgt cttccctggg agcagggatg gtatcttagt	6352
caattttttt cccttgagat gaggtctgtg cctgatgtac aacggatact ccataaatgt	6412
ttgacaaacc aacgaagaat gaaaaaaagc ctagtccagac tcccatccaa agtaggaact	6472
atctctttta cattcttgac tcactatcac tttacctcaa attgaacaga ttccatgacg	6532
gaacttcatt cttcacaaac tagccagtga catgtgggac agctctggcc agggctctgg	6592
gactgcagtg tacttgcgct ctgcacggtc caggagctgt gatgtggctg tggcttaggg	6652
gaatcctgcc tgcccatgg agttgcgcag cacaaccctg gctccaattg ccagaaggct	6712
ctttttaatg ctgaacaaa atgcgccttt ttttttttg agatggagtt tcactcttgt	6772
tgcccaggct ggagtgcaat ggcgcgatct cagctcactg cagccactgc ctcccaggtt	6832
caagtgattc tcctgcctca gcctcccag tagctgggat tacaggcatg cgtaacaca	6892

```

cccagctaatt tttgtatatt tagtagagac gaggtttctc catgttcgac aggctggtct 6952
cgaactccca cctcagcctc ccaaactgct gggattacag gtgtgagcca ccgtgaccag 7012
ccaatgtgcc ttcttatagt gtctactcat tggcttttgt tctgcccagt gataacaatg 7072
ggataacgcc tgctacacat cttcattgtg aaacccttcc cctgtgctga gattaaatga 7132
actctaagat tattaaatag tatattttcc ttgacagcct agcgtttgat gattttaaag 7192
ccttatgtat aaataaacca aaggaagtaa gcagtcatat tgctaatttg ctaactccta 7252
tctattgaat ggtgaagttt taaaaatttc cccaggtaaag tttaagattc aaacaccatc 7312
tattgagcac ctacattgtg tgccaggtag taaaataggt gctttcatac acatcgcttc 7372
aattcctgtg aggtcagaat tatctctgca ttgaaactt gaggaacat gctcagagt 7432
caagaagctt ccttgctga gatcacctag aaaggaacc tcagagccgg caactgaatc 7492
ttggtccctg tgatgtcaag cccattgctc tccactgca gaacatggcc tctagattaa 7552
tgccaccgat tcaggaacac ctccgacagt cttgaaatac cccatgttg ccttgtttgt 7612
tttttccttc tggtttcttc tattacagtc tcttcattgg aagctctgta ggccaaggcc 7672
agagctgata ctgacacgga gccaatgcag atagcacatc agatgctagg ggtcgctggg 7732
aggattaagg gacttaatct gctaggaaca cctgtacttg aagtggagga ggctaggggg 7792
ccacagttgc tgcttcatta acatagaggt tttggatttt ttctcttgt ggtttgtttt 7852
ttaagtggat tggcagactc cttgttgctt aagagtggct ttctaggcag gccactggca 7912
tctgaattca tcattgacaa taaatgtaag aaattggaat aaaaaagaga gacctgctgt 7972
tattcgcttt tgttctccag tgatttgatt aactcagggc aaggctgaat atcagagtgt 8032
atcgactga agaataataa tccattcagt aatgttatag ttatcctcaa tctaaatatg 8092
tcaactgtca ttttgcgtct tttcaataa aatactgaa aactgtcaaa aaaaaaaaaa 8152
aaaaa 8157

```

```

<210> 2
<211> 1933
<212> PRT
<213> HOMO SAPIENS

```

```

<400> 2

```

```

Met Ala Val Pro Gly Ser Phe Pro Leu Leu Val Glu Gly Ser Trp Gly
1           5           10          15

```

Pro Asp Pro Pro Lys Asn Leu Asn Thr Lys Leu Gln Met Tyr Phe Gln
 20 25 30
 Ser Pro Lys Arg Ser Gly Gly Gly Glu Cys Glu Val Arg Gln Asp Pro
 35 40 45
 Arg Ser Pro Ser Arg Phe Leu Val Phe Phe Tyr Pro Glu Asp Gly Lys
 50 55 60
 Trp Arg Gln Gly Thr His Gly Arg Val Thr Arg Pro Thr Ser Ala Ala
 65 70 75 80
 Ala Val Ala Glu Ala Leu Asn Gly Ala Ala Arg Arg Trp Arg Arg Asn
 85 90 95
 Arg Ala Ser Asn Ser Leu Ser Leu Asp Arg Phe Leu Ser Phe Pro Val
 100 105 110
 Val Val Val Leu Leu Phe Val Val Val Val Val Glu Val Ser Leu Ser
 115 120 125
 Ser Tyr His Pro Phe Leu Ser Phe Pro Val Val Ile Ile Leu Val Trp
 130 135 140
 Gly Arg Lys Leu Ile Lys Lys Arg Gly Lys Ser Gln Arg Phe Leu Val
 145 150 155 160
 Val Leu Gly Asp Ser Gln Gly Ser Arg Gly His Leu Gly Glu Gly Gln
 165 170 175
 Arg Arg Tyr Leu Lys Ser His Cys Leu Asn Val Asn Val Glu Pro Ser
 180 185 190
 Gln Arg Pro His Trp Arg Gly Cys Arg Ser Thr Thr Val Arg Gln Lys
 195 200 205
 Val Leu Glu Arg Lys Asn His Glu Leu Val Trp Gln Gly Lys Gly Thr
 210 215 220
 Phe Lys Leu Thr Val Gln Leu Pro Ala Thr Pro Asp Glu Ile Asp His
 225 230 235 240
 Val Phe Glu Glu Glu Leu Leu Thr Lys Ala Asn Val Ser Glu Glu Leu
 245 250 255
 Asp Thr Lys Leu Pro Leu Asp Gly Gly Leu Asp Lys Met Glu Asp Ile
 260 265 270
 Pro Glu Glu Cys Glu Asn Ile Ser Ser Leu Val Ala Phe Glu Asn Leu
 275 280 285
 Lys Ala Asn Val Thr Asp Ile Met Leu Ile Leu Leu Val Glu Asn Ile
 290 295 300
 Ser Gly Leu Ser Asn Asp Asp Phe Gln Val Glu Ile Ile Arg Asp Phe
 305 310 315 320

Asp Val Ala Val Val Thr Phe Gln Lys His Ile Asp Thr Ile Arg Phe
325 330 335

Val Asp Asp Cys Thr Lys His His Ser Ile Lys Gln Leu Gln Leu Ser
340 345 350

Pro Arg Leu Leu Glu Val Thr Asn Thr Ile Arg Val Glu Asn Leu Pro
355 360 365

Pro Gly Ala Asp Asp Tyr Ser Leu Lys Leu Phe Phe Glu Asn Pro Tyr
370 375 380

Asn Gly Gly Gly Arg Val Ala Asn Val Glu Tyr Phe Pro Glu Glu Ser
385 390 395 400

Ser Ala Leu Ile Glu Phe Phe Asp Arg Lys Val Leu Asp Thr Ile Met
405 410 415

Ala Thr Lys Leu Asp Phe Asn Lys Met Pro Leu Ser Val Phe Pro Tyr
420 425 430

Tyr Ala Ser Leu Gly Thr Ala Leu Tyr Gly Lys Glu Lys Pro Leu Ile
435 440 445

Lys Leu Pro Ala Pro Phe Glu Glu Ser Leu Asp Leu Pro Leu Trp Lys
450 455 460

Phe Leu Gln Lys Lys Asn His Leu Ile Glu Glu Ile Asn Asp Glu Met
465 470 475 480

Arg Arg Cys His Cys Glu Leu Thr Trp Ser Gln Leu Ser Gly Lys Val
485 490 495

Thr Ile Arg Pro Ala Ala Thr Leu Val Asn Glu Gly Arg Pro Arg Ile
500 505 510

Lys Thr Trp Gln Ala Asp Thr Ser Thr Thr Leu Ser Ser Ile Arg Ser
515 520 525

Lys Tyr Lys Val Asn Pro Ile Lys Val Asp Pro Thr Met Trp Asp Thr
530 535 540

Ile Lys Asn Asp Val Lys Asp Asp Arg Ile Leu Ile Glu Phe Asp Thr
545 550 555 560

Leu Lys Glu Met Val Ile Leu Ala Gly Lys Ser Glu Asp Val Gln Ser
565 570 575

Ile Glu Val Gln Val Arg Glu Leu Ile Glu Ser Thr Thr Gln Lys Ile
580 585 590

Lys Arg Glu Glu Gln Ser Leu Lys Glu Lys Met Ile Ile Ser Pro Gly
595 600 605

Arg Tyr Phe Leu Leu Cys His Ser Ser Leu Leu Asp His Leu Leu Thr
 610 615 620
 Glu Cys Pro Glu Ile Glu Ile Cys Tyr Asp Arg Val Thr Gln His Leu
 625 630 635 640
 Cys Leu Lys Gly Pro Ser Ala Asp Val Tyr Lys Ala Lys Cys Glu Ile
 645 650 655
 Gln Glu Lys Val Tyr Thr Met Ala Gln Lys Asn Ile Gln Val Ser Pro
 660 665 670
 Glu Ile Phe Gln Phe Leu Gln Gln Val Asn Trp Lys Glu Phe Ser Lys
 675 680 685
 Cys Leu Phe Ile Ala Gln Lys Ile Leu Ala Leu Tyr Glu Leu Glu Gly
 690 695 700
 Thr Thr Val Leu Leu Thr Ser Cys Ser Ser Glu Ala Leu Leu Glu Ala
 705 710 715 720
 Glu Lys Gln Met Leu Ser Ala Leu Asn Tyr Lys Arg Ile Glu Val Glu
 725 730 735
 Asn Lys Glu Val Leu His Gly Lys Lys Trp Lys Gly Leu Thr His Asn
 740 745 750
 Leu Leu Lys Lys Gln Asn Ser Ser Pro Asn Thr Val Ile Ile Asn Glu
 755 760 765
 Leu Thr Ser Glu Thr Thr Ala Glu Val Ile Ile Thr Gly Cys Val Lys
 770 775 780
 Glu Val Asn Glu Thr Tyr Lys Leu Leu Phe Asn Phe Val Glu Gln Asn
 785 790 795 800
 Met Lys Ile Glu Arg Leu Val Glu Val Lys Pro Ser Leu Val Ile Asp
 805 810 815
 Tyr Leu Lys Thr Glu Lys Lys Leu Phe Trp Pro Lys Ile Lys Lys Val
 820 825 830
 Asn Val Gln Val Ser Phe Asn Pro Glu Asn Lys Gln Lys Gly Ile Leu
 835 840 845
 Leu Thr Gly Ser Lys Thr Glu Val Leu Lys Ala Val Asp Ile Val Lys
 850 855 860
 Gln Val Trp Asp Ser Val Cys Val Lys Ser Val His Thr Asp Lys Pro
 865 870 875 880
 Gly Ala Lys Gln Phe Phe Gln Asp Lys Ala Arg Phe Tyr Gln Ser Glu
 885 890 895
 Ile Lys Arg Leu Phe Gly Cys Tyr Ile Glu Leu Gln Glu Asn Glu Val
 900 905 910

Met Lys Glu Gly Gly Ser Pro Ala Gly Gln Lys Cys Phe Ser Arg Thr
 915 920 925

Val Leu Ala Pro Gly Val Val Leu Ile Val Gln Gln Gly Asp Leu Ala
 930 935 940

Arg Leu Pro Val Asp Val Val Val Asn Ala Ser Asn Glu Asp Leu Lys
 945 950 955 960

His Tyr Gly Gly Leu Ala Ala Ala Leu Ser Lys Ala Ala Gly Pro Glu
 965 970 975

Leu Gln Ala Asp Cys Asp Gln Ile Val Lys Arg Glu Gly Arg Leu Leu
 980 985 990

Pro Gly Asn Ala Thr Ile Ser Lys Ala Gly Lys Leu Pro Tyr His His
 995 1000 1005

Val Ile His Ala Val Gly Pro Arg Trp Ser Gly Tyr Glu Ala Pro
 1010 1015 1020

Arg Cys Val Tyr Leu Leu Arg Arg Ala Val Gln Leu Ser Leu Cys
 1025 1030 1035

Leu Ala Glu Lys Tyr Lys Tyr Arg Ser Ile Ala Ile Pro Ala Ile
 1040 1045 1050

Ser Ser Gly Val Phe Gly Phe Pro Leu Gly Arg Cys Val Glu Thr
 1055 1060 1065

Ile Val Ser Ala Ile Lys Glu Asn Phe Gln Phe Lys Lys Asp Gly
 1070 1075 1080

His Cys Leu Lys Glu Ile Tyr Leu Val Asp Val Ser Glu Lys Thr
 1085 1090 1095

Val Glu Ala Phe Ala Glu Ala Val Lys Thr Val Phe Lys Ala Thr
 1100 1105 1110

Leu Pro Asp Thr Ala Ala Pro Pro Gly Leu Pro Pro Ala Ala Ala
 1115 1120 1125

Gly Pro Gly Lys Thr Ser Trp Glu Lys Gly Ser Leu Val Ser Pro
 1130 1135 1140

Gly Gly Leu Gln Met Leu Leu Val Lys Glu Gly Val Gln Asn Ala
 1145 1150 1155

Lys Thr Asp Val Val Val Asn Ser Val Pro Leu Asp Leu Val Leu
 1160 1165 1170

Ser Arg Gly Pro Leu Ser Lys Ser Leu Leu Glu Lys Ala Gly Pro
 1175 1180 1185

Glu Leu Gln Glu Glu Leu Asp Thr Val Gly Gln Gly Val Ala Val
 1190 1195 1200
 Ser Met Gly Thr Val Leu Lys Thr Ser Ser Trp Asn Leu Asp Cys
 1205 1210 1215
 Arg Tyr Val Leu His Val Val Ala Pro Glu Trp Arg Asn Gly Ser
 1220 1225 1230
 Thr Ser Ser Leu Lys Ile Met Glu Asp Ile Ile Arg Glu Cys Met
 1235 1240 1245
 Glu Ile Thr Glu Ser Leu Ser Leu Lys Ser Ile Ala Phe Pro Ala
 1250 1255 1260
 Ile Gly Thr Gly Asn Leu Gly Phe Pro Lys Asn Ile Phe Ala Glu
 1265 1270 1275
 Leu Ile Ile Ser Glu Val Phe Lys Phe Ser Ser Lys Asn Gln Leu
 1280 1285 1290
 Lys Thr Leu Gln Glu Val His Phe Leu Leu His Pro Ser Asp His
 1295 1300 1305
 Glu Asn Ile Gln Ala Phe Ser Asp Glu Phe Ala Arg Arg Ala Asn
 1310 1315 1320
 Gly Asn Leu Val Ser Asp Lys Ile Pro Lys Ala Lys Asp Thr Gln
 1325 1330 1335
 Gly Phe Tyr Gly Thr Val Ser Ser Pro Asp Ser Gly Val Tyr Glu
 1340 1345 1350
 Met Lys Ile Gly Ser Ile Ile Phe Gln Val Ala Ser Gly Asp Ile
 1355 1360 1365
 Thr Lys Glu Glu Thr Asp Val Ile Val Asn Ser Thr Ser Asn Ser
 1370 1375 1380
 Phe Asn Leu Lys Ala Gly Val Ser Lys Ala Ile Leu Glu Cys Ala
 1385 1390 1395
 Gly Gln Asn Val Glu Arg Glu Cys Ser Gln Gln Ala Gln Gln Arg
 1400 1405 1410
 Lys Asn Asp Tyr Ile Ile Thr Gly Gly Gly Phe Leu Arg Cys Lys
 1415 1420 1425
 Asn Ile Ile His Val Ile Gly Gly Asn Asp Val Lys Ser Ser Val
 1430 1435 1440
 Ser Ser Val Leu Gln Glu Cys Glu Lys Lys Asn Tyr Ser Ser Ile
 1445 1450 1455
 Cys Leu Pro Ala Ile Gly Thr Gly Asn Ala Lys Gln His Pro Asp
 1460 1465 1470

Lys Val	Ala Glu Ala Ile Ile	Asp Ala Ile Glu Asp	Phe Val Gln
1475	1480	1485	
Lys Gly	Ser Ala Gln Ser Val	Lys Lys Val Lys Val	Val Ile Phe
1490	1495	1500	
Leu Pro	Gln Val Leu Asp Val	Phe Tyr Ala Asn Met	Lys Lys Arg
1505	1510	1515	
Glu Gly	Thr Gln Leu Ser Ser	Gln Gln Ser Val Met	Ser Lys Leu
1520	1525	1530	
Ala Ser	Phe Leu Gly Phe Ser	Lys Gln Ser Pro Gln	Lys Lys Asn
1535	1540	1545	
His Leu	Val Leu Glu Lys Lys	Thr Glu Ser Ala Thr	Phe Arg Val
1550	1555	1560	
Cys Gly	Glu Asn Val Thr Cys	Val Glu Tyr Ala Ile	Ser Trp Leu
1565	1570	1575	
Gln Asp	Leu Ile Glu Lys Glu	Gln Cys Pro Tyr Thr	Ser Glu Asp
1580	1585	1590	
Glu Cys	Ile Lys Asp Phe Asp	Glu Lys Glu Tyr Gln	Glu Leu Asn
1595	1600	1605	
Glu Leu	Gln Lys Lys Leu Asn	Ile Asn Ile Ser Leu	Asp His Lys
1610	1615	1620	
Arg Pro	Leu Ile Lys Val Leu	Gly Ile Ser Arg Asp	Val Met Gln
1625	1630	1635	
Ala Arg	Asp Glu Ile Glu Ala	Met Ile Lys Arg Val	Arg Leu Ala
1640	1645	1650	
Lys Glu	Gln Glu Ser Arg Ala	Asp Cys Ile Ser Glu	Phe Ile Glu
1655	1660	1665	
Trp Gln	Tyr Asn Asp Asn Asn	Thr Ser His Cys Phe	Asn Lys Met
1670	1675	1680	
Thr Asn	Leu Lys Leu Glu Asp	Ala Arg Arg Glu Lys	Lys Lys Thr
1685	1690	1695	
Val Asp	Val Lys Ile Asn His	Arg His Tyr Thr Val	Asn Leu Asn
1700	1705	1710	
Thr Tyr	Thr Ala Thr Asp Thr	Lys Gly His Ser Leu	Ser Val Gln
1715	1720	1725	
Arg Leu	Thr Lys Ser Lys Val	Asp Ile Pro Ala His	Trp Ser Asp
1730	1735	1740	

Met Lys Gln Gln Asn Phe Cys Val Val Glu Leu Leu Pro Ser Asp
 1745 1750 1755
 Pro Glu Tyr Asn Thr Val Ala Ser Lys Phe Asn Gln Thr Cys Ser
 1760 1765 1770
 His Phe Arg Ile Glu Lys Ile Glu Arg Ile Gln Asn Pro Asp Leu
 1775 1780 1785
 Trp Asn Ser Tyr Gln Ala Lys Lys Lys Thr Met Asp Ala Lys Asn
 1790 1795 1800
 Gly Gln Thr Met Asn Glu Lys Gln Leu Phe His Gly Thr Asp Ala
 1805 1810 1815
 Gly Ser Val Pro His Val Asn Arg Asn Gly Phe Asn Arg Ser Tyr
 1820 1825 1830
 Ala Gly Lys Asn Ala Val Ala Tyr Gly Lys Gly Thr Tyr Phe Ala
 1835 1840 1845
 Val Asn Ala Asn Tyr Ser Ala Asn Asp Thr Tyr Ser Arg Pro Asp
 1850 1855 1860
 Ala Asn Gly Arg Lys His Val Tyr Tyr Val Arg Val Leu Thr Gly
 1865 1870 1875
 Ile Tyr Thr His Gly Asn His Ser Leu Ile Val Pro Pro Ser Lys
 1880 1885 1890
 Asn Pro Gln Asn Pro Thr Asp Leu Tyr Asp Thr Val Thr Asp Asn
 1895 1900 1905
 Val His His Pro Ser Leu Phe Val Ala Phe Tyr Asp Tyr Gln Ala
 1910 1915 1920
 Tyr Pro Glu Tyr Leu Ile Thr Phe Arg Lys
 1925 1930

<210> 3
 <211> 4135
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (36) ..(1892)

<400> 3

ccgagtggtc aataaaatat tccaggcatt ttcag atg aat ttg ccc aga agg
 Met Asn Leu Pro Arg Arg
 1 5

gtt aag gaa aat ctc gtc agt gac aaa ttt ccg aag gct aaa gat aca Val Lys Glu Asn Leu Val Ser Asp Lys Phe Pro Lys Ala Lys Asp Thr 10 15 20	101
caa ggt ttt tat ggg act gtt tct agc cct gat tca ggt gtg tat gaa Gln Gly Phe Tyr Gly Thr Val Ser Ser Pro Asp Ser Gly Val Tyr Glu 25 30 35	149
atg-aag att ggc-tcc- atc-atc-ttc -cag gtg gct tct gga gat atc acg Met Lys Ile Gly Ser Ile Ile Phe Gln Val Ala Ser Gly Asp Ile Thr 40 45 50	197
aaa gaa gag gca gat gtg att gta aat tca aca tca aac tca ttc aat Lys Glu Glu Ala Asp Val Ile Val Asn Ser Thr Ser Asn Ser Phe Asn 55 60 65 70	245
ctc aaa gca ggg gtc tcc aaa gca att tta gaa tgt gct gga caa aat Leu Lys Ala Gly Val Ser Lys Ala Ile Leu Glu Cys Ala Gly Gln Asn 75 80 85	293
gta gaa agg gaa tgt tct cag caa gct cag cag cgc aaa aat gat tat Val Glu Arg Glu Cys Ser Gln Gln Ala Gln Gln Arg Lys Asn Asp Tyr 90 95 100	341
ata atc acc gga ggt gga ttt ttg agg tgc aag aat atc att cat gta Ile Ile Thr Gly Gly Gly Phe Leu Arg Cys Lys Asn Ile Ile His Val 105 110 115	389
att ggt gga aat gat gtc aag agt tca gtt tcc tct gtt ttg cag gag Ile Gly Gly Asn Asp Val Lys Ser Ser Val Ser Ser Val Leu Gln Glu 120 125 130	437
tgt gaa aaa aaa aat tac tca tcc att tgc ctc cca gcc att ggg aca Cys Glu Lys Lys Asn Tyr Ser Ser Ile Cys Leu Pro Ala Ile Gly Thr 135 140 145 150	485
gga aat gcc aaa caa cac cca gat aag gtt gct gaa gcc ata att gat Gly Asn Ala Lys Gln His Pro Asp Lys Val Ala Glu Ala Ile Ile Asp 155 160 165	533
gcc att gaa gac ttt gtc cag aaa gga tca gcc cag tct gtg aaa aaa Ala Ile Glu Asp Phe Val Gln Lys Gly Ser Ala Gln Ser Val Lys Lys 170 175 180	581
gtt aaa gtt gtt atc ttt ctg cct caa gta ctg gat gtg ttt tat gct Val Lys Val Val Ile Phe Leu Pro Gln Val Leu Asp Val Phe Tyr Ala 185 190 195	629
aac atg aag aaa aga gaa ggg act cag ctt tct tcc caa cag tct gtg Asn Met Lys Lys Arg Glu Gly Thr Gln Leu Ser Ser Gln Gln Ser Val 200 205 210	677
atg tct aaa ctt gca tca ttt ttg ggc ttt tca aag caa tct ccc caa Met Ser Lys Leu Ala Ser Phe Leu Gly Phe Ser Lys Gln Ser Pro Gln 215 220 225 230	725

aaa aag aat cat ttg gtt ttg gaa aag aaa aca gaa tca gca act ttt Lys Lys Asn His Leu Val Leu Glu Lys Lys Thr Glu Ser Ala Thr Phe 235 240 245	773
cgg gtg tgt ggt gaa aat gtc acg tgt gtg gaa tat gct atc tcc tgg Arg Val Cys Gly Glu Asn Val Thr Cys Val Glu Tyr Ala Ile Ser Trp 250 255 260	821
cta caa gac ctg att gaa aaa gaa cag tgt cct tac acc agt gaa gat Leu Gln Asp Leu Ile Glu Lys Glu Gln Cys Pro Tyr Thr Ser Glu Asp 265 270 275	869
gag tgc atc aaa gac ttt gat gaa aag gag tat cag gag ttg aat gag Glu Cys Ile Lys Asp Phe Asp Glu Lys Glu Tyr Gln Glu Leu Asn Glu 280 285 290	917
ctg cag aag aag tta aat att aac att tcc ctg gac cat aag aga cct Leu Gln Lys Lys Leu Asn Ile Asn Ile Ser Leu Asp His Lys Arg Pro 295 300 305 310	965
ttg att aag gtt ttg gga att agc aga gat gtg atg cag gct aga gat Leu Ile Lys Val Leu Gly Ile Ser Arg Asp Val Met Gln Ala Arg Asp 315 320 325	1013
gaa att gag gcg atg atc aag aga gtt cga ttg gcc aaa gaa cag gaa Glu Ile Glu Ala Met Ile Lys Arg Val Arg Leu Ala Lys Glu Gln Glu 330 335 340	1061
tcc cgg gca gat tgt atc agt gag ttt ata gaa tgg cag tat aat gac Ser Arg Ala Asp Cys Ile Ser Glu Phe Ile Glu Trp Gln Tyr Asn Asp 345 350 355	1109
aat aac act tct cat tgt ttt aac aaa atg acc aat ctg aaa tta gag Asn Asn Thr Ser His Cys Phe Asn Lys Met Thr Asn Leu Lys Leu Glu 360 365 370	1157
gat gca agg aga gaa aag aaa aaa aca gtt gat gtc aaa att aat cat Asp Ala Arg Arg Glu Lys Lys Lys Thr Val Asp Val Lys Ile Asn His 375 380 385 390	1205
cgg cac tac aca gtg aac ttg aac aca tac act gcc aca gac aca aag Arg His Tyr Thr Val Asn Leu Asn Thr Tyr Thr Ala Thr Asp Thr Lys 395 400 405	1253
ggc cac agt tta tct gtt cag cgc ctc acg aaa tcc aaa gtt gac atc Gly His Ser Leu Ser Val Gln Arg Leu Thr Lys Ser Lys Val Asp Ile 410 415 420	1301
cct gca cac tgg agt gat atg aag cag cag aat ttc tgt gtg gtg gag Pro Ala His Trp Ser Asp Met Lys Gln Gln Asn Phe Cys Val Val Glu 425 430 435	1349
ctg ctg cct agt gat cct gag tac aac acg gtg gca agc aag ttt aat Leu Leu Pro Ser Asp Pro Glu Tyr Asn Thr Val Ala Ser Lys Phe Asn 440 445 450	1397

cag acc tgc tca cac ttc aga ata gag aag att gag agg atc cag aat Gln Thr Cys Ser His Phe Arg Ile Glu Lys Ile Glu Arg Ile Gln Asn 455 460 465 470	1445
cca gat ctc tgg aat agc tac cag gca aag aaa aaa act atg gat gcc Pro Asp Leu Trp Asn Ser Tyr Gln Ala Lys Lys Lys Thr Met Asp Ala 475 480 485	1493
aag-aat-ggc-cag-aca-atg-aat gag-aag caa ctc ttc cat ggg aca gat Lys Asn Gly Gln Thr Met Asn Glu Lys Gln Leu Phe His Gly Thr Asp 490 495 500	1541
gcc ggc tcc gtg cca cac gtc aat cga aat ggc ttt aac cgc agc tat Ala Gly Ser Val Pro His Val Asn Arg Asn Gly Phe Asn Arg Ser Tyr 505 510 515	1589
gcc gga aag aat gcc gtg gca tat gga aag gga acc tat ttt gct gtc Ala Gly Lys Asn Ala Val Ala Tyr Gly Lys Gly Thr Tyr Phe Ala Val 520 525 530	1637
aat gcc aat tat tct gcc aat gat acg tac tcc aga cca gat gca aat Asn Ala Asn Tyr Ser Ala Asn Asp Thr Tyr Ser Arg Pro Asp Ala Asn 535 540 545 550	1685
ggg aga aag cat gtg tat tat gtg cga gta ctt act gga atc tat aca Gly Arg Lys His Val Tyr Tyr Val Arg Val Leu Thr Gly Ile Tyr Thr 555 560 565	1733
cat gga aat cat tca tta att gtg cct cct tca aag aac cct caa aat His Gly Asn His Ser Leu Ile Val Pro Pro Ser Lys Asn Pro Gln Asn 570 575 580	1781
cct act gac ctg tat gac act gtc aca gat aat gtg cac cat cca agt Pro Thr Asp Leu Tyr Asp Thr Val Thr Asp Asn Val His His Pro Ser 585 590 595	1829
tta ttt gtg gca ttt tat gac tac caa gca tac cca gag tac ctt att Leu Phe Val Ala Phe Tyr Asp Tyr Gln Ala Tyr Pro Glu Tyr Leu Ile 600 605 610	1877
acg ttt aga aaa taa cactttggta tccttccac aaaattattc tccatttgta Thr Phe Arg Lys 615	1932
catatctagt tgtaaaacaa gttttagctt ttttttttaa ttcctcttaa cagatttttc	1992
taatatccaa ggatcattct ttgtcgctga agtcagtcct tcttcagctt ctctttcata	2052
atggaaatga acttattatc ttgagagcaa ataacttgga aaattttaat gagataatgc	2112
agttgcaact gtgtgtccac aagtatggac atcaaatctg tgggaaaaga acaggtttgt	2172
attttcagga aggagagaat aacagtctta tagacagagg gcacagctaa gcacagctgc	2232
cactgcagga gacaggcccc atgtcaggat gccatagtgc tgtggggagc acagtattac	2292

ccagtgggta gggcttctgt cttccctggg agcagggatg gtatcttagt caattttttt 2352
 cccttgagat gaggtctgtg cctgatgtac aacggatact ccataaatgt ttgacaaacc 2412
 aacgaagaat gaaaaaagc ctagtcagac tcccatccaa agtaggaact atctctttaa 2472
 cattcttgac tcactatcac ttacctcaa attgaacaga ttccatgacg gaacttcatt 2532
 cttcacaac tagccagtga catgtgggac agctctggcc agggctctgg gactgcagtg 2592
 tacttgcgct ctgcacggtc caggagctgt gatgtggctg tggcttaggg gaatcctgcc 2652
 tgcccatgg agttgcgcag cacaaccctg gctccaattg ccagaaggct ctttttaatg 2712
 ctgaaccaa atgcgccctt ttttttttc tgagatggag ttactactt gttgccagg 2772
 ctggagtga atggcgcat ctgagctcac tgcagccact gcctcccagg ttcaagtga 2832
 tctctgcct cagcctcccg agtagctggg attacaggca tgcgctaaca caccagcta 2892
 atttgtatt ttagtagag acgaggttc tccatgttcg acaggctggt ctggaactcc 2952
 cacctcagcc tcccaaactg ctgggattac aggtgtgagc cactgtgacc agccaatgtg 3012
 cttcttata gtgtctactc attggtctt gttctgcca gtgataacaa tgggataacg 3072
 cctgctacac atcttcattg tgaaaccctt cccctgtgct gagattaaat gaactctgag 3132
 attattaaat agtatattt ccttgacagc ctgagcttg atgattttaa agccttatgt 3192
 ataaataaac caaaggaagt aagcagtcatt attgctaatt tgctaactcc tatctattga 3252
 atggtgaagt tttaaaaatt tccccaggta agtttaagat tcaaacacca tctattgagc 3312
 acctacattg tgtgccaggt agtaaaatag gtgctttcat acacattgtc tcaattcctg 3372
 tgaggtcaga attatctctg catttgaac ttgaggaaac atgctcagag tgcaagaagc 3432
 ttccttgctt gagatcacct agaaaggaac cctcagagcc ggcaactgaa tcttggtccc 3492
 tgtgatgtca agccattgc tctccactg cagaacatgg cctctagatt aatgccaccg 3552
 attcaggaac acctccgaca gtcttgaaat acccccatgt tgccttgttt gtttttctt 3612
 tctggcttct tctattacag tctcttcatt ggaagctctg taggccaagg ccagagctga 3672
 tactgacacg gagccaatgc agatagcaca tcagatgcta ggggtcgctg ggaggattaa 3732
 gggacttaat ctgctaggaa cacctgtact tgaagtggag gaggctaggg ggccacagtt 3792
 gctgcttcat taacatagag gttttggatt ttttctctt gtggtttgtt ttttaagtgg 3852
 attggcagac tccttgttgc ttaagagtgg ctttctaggc aggccactgg catctgaatt 3912
 catcattgac aataaatgta agaaattgga ataaaaaga gaggcctgct gttattcgct 3972

tttgttctcc agtgatttga ttaactcagg gcaaggctga atatcagagt gtatcgact 4032
gaagaataat aatccattca gtaatgttat agttatcctc aatctaaata tgtcaactgt 4092
cattttgcta cttttcaaata aaaatacttg aaaactgtca aaa 4135

<210> 4
<211> 618
<212> PRT
<213> Homo sapiens

<400> 4

Met Asn Leu Pro Arg Arg Val Lys Glu Asn Leu Val Ser Asp Lys Phe
1 5 10 15
Pro Lys Ala Lys Asp Thr Gln Gly Phe Tyr Gly Thr Val Ser Ser Pro
20 25 30
Asp Ser Gly Val Tyr Glu Met Lys Ile Gly Ser Ile Ile Phe Gln Val
35 40 45
Ala Ser Gly Asp Ile Thr Lys Glu Glu Ala Asp Val Ile Val Asn Ser
50 55 60
Thr Ser Asn Ser Phe Asn Leu Lys Ala Gly Val Ser Lys Ala Ile Leu
65 70 75 80
Glu Cys Ala Gly Gln Asn Val Glu Arg Glu Cys Ser Gln Gln Ala Gln
85 90 95
Gln Arg Lys Asn Asp Tyr Ile Ile Thr Gly Gly Gly Phe Leu Arg Cys
100 105 110
Lys Asn Ile Ile His Val Ile Gly Gly Asn Asp Val Lys Ser Ser Val
115 120 125
Ser Ser Val Leu Gln Glu Cys Glu Lys Lys Asn Tyr Ser Ser Ile Cys
130 135 140
Leu Pro Ala Ile Gly Thr Gly Asn Ala Lys Gln His Pro Asp Lys Val
145 150 155 160
Ala Glu Ala Ile Ile Asp Ala Ile Glu Asp Phe Val Gln Lys Gly Ser
165 170 175
Ala Gln Ser Val Lys Lys Val Lys Val Val Ile Phe Leu Pro Gln Val
180 185 190
Leu Asp Val Phe Tyr Ala Asn Met Lys Lys Arg Glu Gly Thr Gln Leu
195 200 205
Ser Ser Gln Gln Ser Val Met Ser Lys Leu Ala Ser Phe Leu Gly Phe
210 215 220

Ser Lys Gln Ser Pro Gln Lys Lys Asn His Leu Val Leu Glu Lys Lys
 225 230 235 240
 Thr Glu Ser Ala Thr Phe Arg Val Cys Gly Glu Asn Val Thr Cys Val
 245 250 255
 Glu Tyr Ala Ile Ser Trp Leu Gln Asp Leu Ile Glu Lys Glu Gln Cys
 260 265 270
 Pro Tyr Thr Ser Glu Asp Glu Cys Ile Lys Asp Phe Asp Glu Lys Glu
 275 280 285
 Tyr Gln Glu Leu Asn Glu Leu Gln Lys Lys Leu Asn Ile Asn Ile Ser
 290 295 300
 Leu Asp His Lys Arg Pro Leu Ile Lys Val Leu Gly Ile Ser Arg Asp
 305 310 315 320
 Val Met Gln Ala Arg Asp Glu Ile Glu Ala Met Ile Lys Arg Val Arg
 325 330 335
 Leu Ala Lys Glu Gln Glu Ser Arg Ala Asp Cys Ile Ser Glu Phe Ile
 340 345 350
 Glu Trp Gln Tyr Asn Asp Asn Asn Thr Ser His Cys Phe Asn Lys Met
 355 360 365
 Thr Asn Leu Lys Leu Glu Asp Ala Arg Arg Glu Lys Lys Lys Thr Val
 370 375 380
 Asp Val Lys Ile Asn His Arg His Tyr Thr Val Asn Leu Asn Thr Tyr
 385 390 395 400
 Thr Ala Thr Asp Thr Lys Gly His Ser Leu Ser Val Gln Arg Leu Thr
 405 410 415
 Lys Ser Lys Val Asp Ile Pro Ala His Trp Ser Asp Met Lys Gln Gln
 420 425 430
 Asn Phe Cys Val Val Glu Leu Leu Pro Ser Asp Pro Glu Tyr Asn Thr
 435 440 445
 Val Ala Ser Lys Phe Asn Gln Thr Cys Ser His Phe Arg Ile Glu Lys
 450 455 460
 Ile Glu Arg Ile Gln Asn Pro Asp Leu Trp Asn Ser Tyr Gln Ala Lys
 465 470 475 480
 Lys Lys Thr Met Asp Ala Lys Asn Gly Gln Thr Met Asn Glu Lys Gln
 485 490 495
 Leu Phe His Gly Thr Asp Ala Gly Ser Val Pro His Val Asn Arg Asn
 500 505 510

Gly Phe Asn Arg Ser Tyr Ala Gly Lys Asn Ala Val Ala Tyr Gly Lys
 515 520 525

Gly Thr Tyr Phe Ala Val Asn Ala Asn Tyr Ser Ala Asn Asp Thr Tyr
 530 535 540

Ser Arg Pro Asp Ala Asn Gly Arg Lys His Val Tyr Tyr Val Arg Val
 545 550 555 560

Leu Thr Gly Ile Tyr Thr His Gly Asn His Ser Leu Ile Val Pro Pro
 565 570 575

Ser Lys Asn Pro Gln Asn Pro Thr Asp Leu Tyr Asp Thr Val Thr Asp
 580 585 590

Asn Val His His Pro Ser Leu Phe Val Ala Phe Tyr Asp Tyr Gln Ala
 595 600 605

Tyr Pro Glu Tyr Leu Ile Thr Phe Arg Lys
 610 615

CLAIMS

1. An isolated polypeptide comprising a sequence selected from:
 - (iii) the amino acid sequence of SEQ ID NO: 2;
 - (iv) an allelic or species variant of a sequence of (i);
 - (iii) a variant of a sequence of (i) having at least 60% identity over the full length of SEQ ID NO: 2 and having substantially similar function selected from immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity; or
 - (iv) a fragment of (i) or (ii) which does not have the amino acid sequence of SEQ ID NO: 4, an allelic or species variant of the sequence of SEQ ID NO: 4 or a fragment thereof and which retains substantially similar function selected from immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity.
2. A variant or fragment of the polypeptide defined by the amino acid sequence set forth in SEQ. ID. No. 2 suitable for raising specific antibodies for said polypeptide and/or an allelic or species variant thereof.
3. A polynucleotide encoding a polypeptide as claimed in claim 1 or 2.
4. A polynucleotide as claimed in claim 3 which is a cDNA.
5. A polynucleotide encoding a polypeptide as claimed in claim 1, which polynucleotide comprises:
 - (a) the nucleic acid sequence of SEQ ID NO: 1 or the coding sequence thereof and/or a sequence complementary thereto;
 - (b) a sequence which hybridises to a sequence as defined in (a);
 - (c) a sequence that is degenerate as a result of the genetic code to a sequence as defined in (a) or (b); or
 - (d) a sequence having at least 60% identity to a sequence as defined in (a), (b) or (c).

6. An expression vector comprising a polynucleotide sequence as claimed in any one of claims 3 to 5, which is capable of expressing a polypeptide according to claim 1 or 2.
7. A host cell containing an expression vector according to claim 6.
8. An antibody specific for a polypeptide as claimed in claim 1 or claim 2.
9. An isolated polynucleotide which directs expression *in vivo* of a polypeptide as claimed in claim 1.
10. A polypeptide as claimed in claim 1 or a polynucleotide as claimed in claim 9 for use in therapeutic treatment of a human or non-human animal.
11. A pharmaceutical composition comprising a polypeptide as claimed in claim 1 or a polynucleotide as claimed in claim 9 and a pharmaceutically acceptable carrier or diluent.
12. Use of a polypeptide as claimed in claim 1 or a polynucleotide as claimed in claim 9 in the preparation of medicament for use in therapy as an anti-viral, anti-tumour or immunomodulatory agent.
13. A method of treating a patient having a Type 1 interferon treatable disease, which comprises administering to said patient an effective amount of a polypeptide as claimed in claim 1 or a polynucleotide as claimed in claim 9.
14. A method of producing a polypeptide according to claim 1 or 2, which method comprises culturing host cells as claimed in claim 7 under conditions suitable for obtaining expression of the polypeptide and isolating the said polypeptide.

15. A method of identifying a compound having immunomodulatory activity and/or anti-viral activity and/or anti-tumour activity comprising providing a cell capable of expressing the polypeptide of SEQ. ID. No. 2 or a naturally-occurring variant thereof having at least 60 % identity over the full length of SEQ ID NO: 2, incubating said cell with a compound under test and monitoring for upregulation of the gene encoding said polypeptide or variant.
16. A polynucleotide capable of expressing *in vivo* an antisense sequence to a coding sequence for the amino acid sequence defined by SEQ. ID. No.2 or a naturally-occurring variant of said coding sequence having at least 60 % identity over the full length of said coding sequence for use in therapeutic treatment of a human or non-human animal.
17. An antibody as claimed in claim 8 for use in therapeutic treatment.
18. A set of primers for nucleic acid amplification which target sequences within a cDNA as claimed in claim 4.
19. A nucleic acid probe derived from a polynucleotide as claimed in any one of claims 3 to 5.
20. A probe as claimed in claim 19 which is attached to a solid support.
21. A method of predicting responsiveness of a patient to treatment with a Type 1 interferon, which comprises determining the level of the protein defined by the amino acid sequence set forth in SEQ. ID. No. 2 or a naturally-occurring variant thereof having at least 60 % identity over the full length of SEQ ID NO: 2, or the corresponding mRNA, in a cell sample from said patient, wherein said sample is obtained from said patient following administration of a Type 1 interferon or is treated prior to said determining with a Type 1 interferon *in vitro*.

22. A method as claimed in claim 21 wherein the interferon administered prior to obtaining said sample or used to treat said sample *in vitro* is the interferon proposed for treatment of said patient.
23. A method as claimed in claim 21 or claim 22 wherein a sample comprising ~~peripheral blood mononuclear cells isolated from a blood sample of the patient is~~ treated with a Type 1 interferon *in vitro*.
24. A method as claimed in any one of claims 21 to 23 wherein said determining comprises determining the level of mRNA encoding the protein defined by the sequence set forth in SEQ. ID. No. 2 or a naturally-occurring variant of said protein having at least 60% identity over the full length of SEQ ID NO: 2.
25. A non-human transgenic animal capable of expressing a polypeptide that is claimed in claim 1.

ABSTRACT**INTERFERON- α INDUCED GENE**

The present invention relates to identification of a gene upregulated by interferon- α administration corresponding to the cDNA sequence set forth in SEQ. ID. No. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon- α and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.